[{"article": "Even incurable causes of age-related vision loss such as glaucoma and age-related macular degeneration \u201care highly treatable, so we can reduce the amount of vision loss that people suffer from if they\u2019re detected early.\u201d\nThe good news, Whitson added, is that poor vision is one of the few risk factors for cognitive decline that is potentially modifiable.\n\u201cThis study provides additional evidence that would suggest that people who can keep their vision healthy as they age might also be protecting their cognitive health,\u201d said Dr. Heather E. Whitson of Duke University School of Medicine and Durham VA Medical Center, who wasn\u2019t involved in the research.\nOver the course of the study, average visual decline was roughly equivalent to losing the ability to read one line of an eye chart.\nThe results suggest that vision fixes, like a new eyeglass prescription or surgery to remove cataracts, can go a long way toward helping older people stay mentally sharp, said lead author D. Diane Zheng of the University of Miami Miller School of Medicine.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The study was funded by the National Eye Institute and the Jane Kroger Fund. It would have been beneficial to include the funding sources in the story. However, omitting the name of a government or non-profit funder does not merit a Not Satisfactory rating.", "answer": 1}, {"article": "In coherent breathing, the goal is to breathe at a rate of five breaths per minute, which generally translates into inhaling and exhaling to the count of six.\nThe subjects\u2019 saliva was tested at various intervals during the exercise.\nThe research was presented in May at the International Congress on Integrative Medicine and Health in Las Vegas.\nThe findings were published in the journal BMC Complementary and Alternative Medicine in August.\nWhile the study was small and lacked a control group, Dr. Streeter and her colleagues are planning a randomized controlled trial to further test the intervention.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "This is the biggest shortcoming of the article: All of those quoted have research and/or books to promote. The story could have used some sources who have a broader view of therapeutic approaches to stress.", "answer": 0}, {"article": "\"This is really the gold standard.\nA new cold and flu test can precisely diagnose a dozen winter ailments and reduce unneeded use of antibiotics, says the company that sells it.\nPhysicians say the test is accurate and the most comprehensive available, but some say its long processing time limits usefulness in emergency rooms.\nThe test is expected to be used mainly in hospitals and emergency rooms, but doctors can send the swab to a local lab.\nAccording to data submitted to the FDA, the test detects each virus 78% to 100% of the time, depending on the type, and has few false positives.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "This story draws information from a variety of credible sources, including the FDA, a\u00a0researcher who published results\u00a0indicating that the flu is under-diagnosed in children,\u00a0and an independent emergency room physician.\u00a0 Information from the manufacturer is also given.", "answer": 1}, {"article": "Low sperm count, or oligospermia, is a main cause of male infertility.\nAs SpermCheck\u2019s website puts it, a \u201ctrip to a fertility clinic for a semen analysis is not for everyone.\nFor women who are having trouble getting pregnant, the test may very well be one they \u2014 and not their squeamish partners \u2014 snap up along with over-the-counter ovulation kits.\nWhen it comes to infertility, the burden seems to often fall on women.\n\u201cMen don\u2019t say, \u2018Let me go to the urologist and give a semen sample.\u2019\u201d That reluctance has created a $440 million-a-year market for male fertility tests in the U.S., Lopez says.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "There is no independent perspective in the story.\u00a0 The only sources quoted are the CEO and the chairman of the company making the test.\n\u00a0", "answer": 0}, {"article": "In general, the risk of developing colorectal cancer varies with age, race, ethnicity and lifestyle.\nDr. Friis emphasized that people should not start taking aspirin or NSAIDs on the basis of the new findings.\nNonaspirin NSAIDs were also protective against colorectal cancer with consistent long-term use, \u201cand there was some indication that even non-continuous use of these agents may be (marginally) effective for the prevention of colorectal cancer,\u201d Dr. Friis said.\nOn the other hand, merely having taken aspirin did not alter the colorectal cancer risk, they reported in Annals of Internal Medicine.\n\u201cSelf-medication with aspirin or non-aspirin NSAIDs is strongly discouraged, due to the possibility of serious adverse events,\u201d Dr. Friis said.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story includes comment from Dr. Gurpreet Singh-Ranger, who apparently was not involved with the study, so we\u2019ll give it a pass. The story\u00a0would have been stronger had it told the reader what made him an authority on the topic.", "answer": 1}, {"article": "For more on childhood obesity, visit the U.S. Centers for Disease Control and Prevention.\nHealth benefits, including weight loss, seem to be a byproduct of the program, said Dr. David Katz, director of the Yale University Prevention Research Center.\n\"This paper importantly suggests that some of the best strategies for controlling weight and promoting health may have little directly to do with either,\" said Katz, who wasn't involved in the study.\n\"The children may be served healthier meals at Head Start than other children.\"\n\"It [also] may be that when kids go to Head Start, it reduces stress in the household and frees up time and resources at home to dedicate to healthier eating patterns,\" she noted.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story provides comments by a source who was not involved in the study, Dr. David Katz of Yale University, explaining the value of the Head Start Program.", "answer": 1}, {"article": "When that occurs, the next step is to examine the suspicious area, with the physician ordering a biopsy or inserting a scope into the lungs to evaluate further.\nAccording to Dubinett, about one in 500 chest X-rays shows a lung nodule of ''indeterminant significance.\"\nIf perfected, the test could help spare patients the need to undergo invasive procedures such as biopsies when lung cancer is suspected, they predict.\nHe is the senior author on the study, presented at the American Association for Cancer Research-International Association for the Study of Lung Cancer's joint conference in Coronado, Calif.\n\nAbout 219,000 new cases of lung cancer were expected to be diagnosed in the U.S. in 2009, according to the American Cancer Society, and about 159,000 deaths were expected.\nJan. 13, 2010 (Coronado, Calif.) -- A blood test under study to help diagnose lung cancer looks promising, researchers reported Tuesday at a cancer meeting in California.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "An independent source was cited, a meeting attendant, and the SomaLogic quotes were added for context. The latter were good for illustrating that the Dubinett group is not the only game in town working on this type of blood test.\nIdeally, the article would have had more independent analysis of the specific results.\u00a0No independent source was used to assess the SomaLogic employee\u2019s claims of their experimental test\u2019s sensitivity.\u00a0Although\u00a0the\u00a0MedPage Today coverage of the study\u00a0is aimed at a professional medical audience, it provides a good example of some of the critical points outside sources can provide about these type of very early results.\nAlthough the article does not identify conflicts of interest, from the MedPage Today article it\u2019s not clear that the investigators disclosed any conflicts of interest in their abstract.", "answer": 1}, {"article": "Consumers can wake up with Red Bull and then wind down with Slow Cow.\nNow, the field includes a slew of new drinks promising a better night's sleep using such ingredients as melatonin, valerian root and - think turkey - tryptophan.\nThe back of the Snooz'n bottle says the beverage will \"combat stress, energy drinks and sleeplessness\" and takes about 30 minutes to take effect.\nOral doses of melatonin haven't worked much better at inducing sleep than a placebo in most studies, Scharf says, and a single, concentrated shot of the stuff doesn't exactly mimic the body's time-release system.\nMelatonin is used for the latter, while ingredients such as valerian root and chamomile take care of the former, Healy says.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes a physician sleep expert, a dietitian, and an employee of one of the beverage companies. There don\u2019t appear to be any conflicts of interest that weren\u2019t properly disclosed.", "answer": 1}, {"article": "A compound in raspberries is being touted as the next new fat burner. But people looking to lose a few pounds may not want to go running to the produce aisle just yet. Scientists say there are no major human studies to support the idea that a berry holds the secret to weight loss.\n\nRaspberry ketones, the organic compounds that give raspberries their aroma, raised hopes as a weight-loss aid after a 2005 study by Japanese researchers found the ketones boosted fat-burning processes in rat cells in a laboratory as long as those...", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story recruits three independent experts to bat down\u00a0unfounded claims about raspberry ketones.", "answer": 1}, {"article": "Pneumonia is a leading cause of death for elderly patients, with over 90 percent of pneumonia-related deaths among those 65 and older.\nDisclosures: The basis for this analysis, The Multicenter Osteopathic Pneumonia Study in the Elderly (MOPSE) clinical trial, was funded by a consortium of foundations including the Foundation for Osteopathic Health Services.\n\"This study should encourage physicians to use their osteopathic techniques when treating older patients with pneumonia.\"\nThe study results published in The Journal of the American Osteopathic Association.\nThe study analyzed 375 patients ages 50 or older who were randomly assigned to three groups, either receiving OMT, a light touch or conventional care only.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "We gave this a pass for barely meeting the criteria. The release notes that the trial was funded by a consortium of foundations including the Foundation for Osteopathic Health Services. It doesn\u2019t specifically disclose potential conflicts of interest but directs readers to the study for \u201cfull details.\u201d\nWhen we looked at the disclosures, it was clear that the researchers were aligned with or officially affiliated with osteopathic institutions and foundations.", "answer": 1}, {"article": "The requested URL /usnews/health/articles/070107/15downs.htm was not found on this server.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story does quote multiple experts. The story should have quoted experts with differing opinions on the value of the new screening recommendations in order to provide some much needed perspective. The story could have been much improved by the addition of quotes from researchers who may have concerns about the broad use of testing or by interviews with women who chose not to be tested.", "answer": 1}, {"article": "Cabozantinib, also known as XL184, is an oral drug designed to limit blood supply to tumors and to block two segments of a pathway used by cancer cells to grow and spread.\nThe drug reduced by 87 percent the risk of disease progression or death.\nOther Phase 2 data presented over the weekend showed that treatment with cabozantinib led to significant tumor shrinkage in 24 percent of patients with metastatic ovarian cancer.\nThe study results were reported on Monday at the American Society of Clinical Oncology\u2019s annual meeting.\nThe disease remained stable in 23 other patients, or 21 percent, and worsened in three.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "No physician or researcher was interviewed \u2013 only the drug company CEO.\u00a0 Not good form in reporting on health news.\u00a0 With thousands of cancer specialists in Chicago for the ASCO conference, was none available?", "answer": 0}, {"article": "\"We have been trying as doctors for centuries to find a treatment that actually reverses heart injury,\" Eduardo Marban, MD, PhD, tells WebMD.\nIt's the first completed, controlled clinical trial showing that scarred heart tissue can be repaired.\nMarban, director of the Cedars-Sinai Heart Institute in Los Angeles, led the study.\nIf so, this could change the nature of medicine.\nHe invented the \"cardiosphere\" culture technique used to create the stem cells and founded the company developing the treatment.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "No interviews with independent sources are in evidence in the story. There is one quote from an accompanying editorial. The bulk of the story is given over to effusive quotes from the lead researcher, Eduardo Marban. We appreciate that the story made note of the fact that \u201cHe invented the \u201ccardiosphere\u201d culture technique used to create the stem cells and founded the company developing the treatment.\u201d We think, though, that his conflict of interest should have prompted a few calls to independent sources.", "answer": 0}, {"article": "Early menopause is often a side effect for women treated with chemotherapy for breast cancer, but a new study reveals some guarded promise for preventing early menopause breast cancer patients.\nPatients were randomly selected to be treated with chemotherapy alone or with chemotherapy and triptorelin, a drug, called a GnRH analogue, that prevents the ovaries from releasing eggs.\nItalian researchers conducted a phase three study that included 281 women with breast cancer, aged 18 to 45 years and who had not experienced menopause.\nThey conclude that using assisted reproductive technology \u2013 such as storing eggs before chemo, is \u201cthe most effective option for fertility preservation.\u201d\nAn accompanying editorial by Dr. Hope S. Rugo and Dr. Mitchell P. Rosen of the University of California-San Francisco says that trptorelin therapy should not be recommended as a standard treatment and should be approached with caution in women with hormone-sensitive disease.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story cited an editorial that accompanied the journal article.\u00a0 However, there was no indication of potential conflicts or lack of conflicts of interest, despite disclosures stated in the journal article.", "answer": 0}, {"article": "During the process, blood is drawn from the patient and then injected back into the pained joint.\nThis therapy has recently been highlighted by several professional football players traveling to Europe for treatment.\nThe cost of the USA-based IRAPjoint\u2122 treatment is $2,000 compared to the reported price of $10,000 for a foreign competitor.\nFinally, a U.S. based company has a solution for America's professional and weekend athletes as well as those struggling with aching or arthritic joints.\nOKLAHOMA CITY, Sept. 7, 2017 /PRNewswire/ -- Arthrokinex announces the release of IRAPjoint\u2122 therapy in the USA.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "This news release was sent out by the clinic that developed and now markets this treatment, so the conflict of interest is fairly obvious. Another big conflict of interest should have been noted, but wasn\u2019t. The one research trial published on this therapy was conducted by a physician who has ownership in the clinic and sits on the company\u2019s board of directors. This fact, which was disclosed in the published study but not the news release, forms a clear conflict of interest.", "answer": 0}, {"article": "\"It gives us encouragement that we may be on to something here.\"\nOverall, however, the limited success in some patients and the complete success in one is good news, he says.\nOne woman who got the investigational vaccine now has no X-ray evidence of cancer, says study researcher James Gulley, MD, PhD.\nAs exciting as that is, he says, \"a lot of work needs to be done to prove whether this can be effective [for more patients].\"\nThe study, funded by the National Cancer Institute, is published in Clinical Cancer Research.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "This is the root of the story\u2019s main shortcoming. Almost all of the information in the story comes from one source: Dr. James\u00a0Gulley, who oversaw the study. Gulley is quite enthusiastic about this vaccine, despite the evidence, and the story needed more perspectives to put this vaccine into a broader context. At the very end, there are a few comments from Dr. Vincent K. Tuohy, who also is working on a breast cancer vaccine. Because of his competing research, he seems to have a conflict, but even putting that aside, his comments were not used to their best effect.", "answer": 0}, {"article": "This type of drug development program, which enrolled patients with different tumors but a common gene mutation, wouldn\u2019t have been possible a decade ago because we knew a lot less about such cancer mutations,\" said Dr. Gottlieb.\n\"Using our breakthrough therapy designation and accelerated approval processes, we support innovation in precision oncology drug development and the evolution of more targeted and effective treatments for cancer patients,\" the FDA stated.\nIts approval reflects advances in the use of biomarkers to guide drug development and the more targeted delivery of medicine.\"\n\"This new site-agnostic oncology therapy isn\u2019t specific to a cancer arising in a particular body organ, such as breast or colon cancer.\nVitrakvi will run further tests of the drug's safety and effectiveness.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "There are no independent sources mentioned in this story, which also doesn\u2019t state that all of the clinical trials have been sponsored by the company selling the drug.", "answer": 0}, {"article": "In a study by researchers from the Hospital Clinic of Barcelona and Loma Linda University, more than 700 older, healthy adults were asked to add either a handful of walnuts to their daily diets or to follow their normal diet without eating nuts.\nWalnuts have long been touted as a healthy, whole food, but new research just upped the homely nut's reputation another notch.\nThe research shows the well-known cholesterol-lowering effect of eating walnuts works equally well in the elderly, even in the long term, the authors reported at the Experimental Biology conference in San Diego.\nOther walnut studies presented at the conference, funded in part by the California Walnut Commission, suggested the omega-3 fatty acid-rich nut may also benefit gut bacteria and help reduce inflammation.\nIt's still important to remember portion control, especially for people on weight loss programs, warned Politi.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Close call on this one, but we\u2019re going with\u00a0Satisfactory, since the story\u00a0did identify that the walnut research was funded by the California Walnut Commission, and an independent nutrition expert was quoted\u2013although she didn\u2019t talk about the study. Ideally, an outside source could have provided commentary on the research, providing insight into the quality of the evidence.", "answer": 1}, {"article": "Like rheumatoid arthritis, osteoarthritis is a chronic, degenerative joint disease.\nStudy researcher Gabriel Chodick, MD, called the risk reduction \"important and meaningful,\" but he says more research is needed to confirm the association.\nThe study appears in the September issue of the journal PLoS Medicine.\nThe regular use of statins was associated with a 42% reduction in rheumatoid arthritis (RA) risk in a newly reported study of patients enrolled in one of Israel's largest health plans .\nBetween 1998 and 2007, 2,578 new cases of rheumatoid arthritis were identified in this group.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "\n\n\nThe story includes comments from an independent source. Although the story does not mention any potential conflicts of interest, none were disclosed by the study authors.", "answer": 1}, {"article": "In the study, men taking an angiotensin receptor blocker had a 24 percent lower incidence of dementia than those taking other cardiovascular drugs.\nThe risk was nearly halved for those taking both angiotensin-targeting drugs.\nWolozin said that it's not clear why the drugs would have a beneficial effect on the brain, but improved blood flow probably plays a role.\nCaution was urged by Dr. Richard B. Lipton, vice chairman of neurology at Albert Einstein College of Medicine in New York City, who has done work on the genetics of Alzheimer's disease.\nCalled angiotensin receptor blockers, these drugs have a greater protective effect against dementia than ACE inhibitors, the study found.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story did quote one independent expert who injected a cautionary note \u2013 in addition to the lead researcher. ", "answer": 1}, {"article": "Hialeah bucket list: All the things you need to do in Hialeah before you die\n\nYou can spend your whole life working on this list.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story obtains information from physicians not associated with the research who can provide a range of perspectives on what screening may or may not offer to provide balance.\u00a0 ", "answer": 1}, {"article": "For men with advanced prostate cancer, the news for decades has been mostly bleak. Until recently, only two treatments had been shown to prolong survival.\n\nResearchers reported Monday that the drug abiraterone, being developed by Johnson & Johnson, extended survival by an average of 3.9 months among men with cancer that has spread beyond the prostate and for whom other treatments have failed. Among men, prostate cancer is the second-leading cancer killer, behind only lung cancer.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "\n\n\nAlthough the story includes an independent expert and notes that the drug is being developed by Johnson & Johnson, it does not tell readers that the trial researcher quoted in the story has had a financial relationship with the drug\u2019s commerical developers. Journal articles about earlier phases of research into this drug noted the researchers\u2019 financial disclosures. The fact that such disclosures may not be included in materials distributed at medical meetings is one more reason to be wary of these presentations.", "answer": 0}, {"article": "\u2022 LPCN 1021 was well tolerated and had a favorable safety profile in the long-term management of hypogonadal patients\n\u2022 No hepatic, cardiac or drug-related serious adverse events were reported\n\u2022 The most common drug-related adverse events for LPCN 1021 and T gel 1.62 percent were acne (2.9 percent vs. 2.9 percent, respectively), headache (0.5 percent vs. 3.8 percent, respectively), weight increase (2.4 percent vs. 0 percent, respectively), hematocrit increase (1.9 percent vs. 0 percent, respectively), liver enzyme level increase (1.4 percent vs. 0 percent, respectively), fatigue (0.5 percent vs. 1.9 percent, respectively), and hypertension (0.5 percent vs. 1.9 percent, respectively)\n\u2022 Lipid parameters (i.e., cholesterol, LDL, HDL, and TG) were comparable between treatment groups at Week 52\n\u2022 Androgenic parameters including hematocrit, hemoglobin, platelet, prothrombin, and prostate-specific antigen (PSA) showed no significant differences in change from baseline to end of study between treatments\n\n\"Based on the results of this study, we might be closer than ever to having an oral form of therapy to treat the millions of men with hypogonadism,\" said Dr. K\u00f6hler.\nFollowing a 13-week efficacy phase, men continued to receive their assigned treatment for up to 52 weeks.\nThe research will be highlighted by study authors during a special press conference to be moderated by Tobias S. K\u00f6hler, MD, MPH, FACS, AUA spokesperson and associate professor of Surgery at Southern Illinois University on May 8, 2016 at 7:30 a.m. PT in the San Diego Convention Center.\n\"Making sure an oral treatment is safe and effective for men and for the children and partners at risk for inadvertent testosterone transference is the top priority, and what we've found so far has shown we're on the right track.\"\nThey returned at weeks 26, 39 and 52 for safety assessments, which included an evaluation of adverse events, clinical laboratory tests and physical examinations.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The news release fails to disclose that all of the study authors have financial ties to the drug manufacturer, Lipocine Inc., as consultants, principal investigators or employees, and that one is the company\u2019s founder.", "answer": 0}, {"article": "The Harvard Medical School affiliates share a clinical staff that delivers inpatient care at Boston Children's Hospital and most outpatient care at Dana-Farber Cancer Institute.\nThe new study grew out of efforts to discover whether different types of cancer are susceptible to Ezh2 inhibitors.\n\"The vast majority of patients with CML do remarkably well on imatinib [Gleevec] and similar drugs: The disease is well controlled and side effects are tolerable,\" says Stuart Orkin, MD, the study's senior author and a pediatric hematologist/oncologist at Dana-Farber/Boston Children's Cancer and Blood Disorders Center.\nJoining senior author Orkin, the study's lead author is Huafeng Xie, PhD, of Dana/Farber/Boston Children's.\nEpizyme, a biopharmaceutical company based in Cambridge, MA, recently opened a pediatric trial of an Ezh2 inhibitor for children with rhabdoid and other tumors.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "We\u2019re told the pharmaceutical company Epizyme opened a phase 1 clinical trial at Dana-Farber/Boston Children\u2019s hospital. We\u2019re also told an NIH grant and Hyundai Hope on Wheels is funding the study. The release also notes\u00a0one of the authors on the study is an employee of Novartis Pharmaceuticals \u2014 which owns the (soon-to-expire) patent for Gleevec, also called Glivec.", "answer": 1}, {"article": "Your skin clears up.\nThe final diet was the three-week Quantum Wellness Cleanse, which Oprah Winfrey made famous.\nVolpe said she noticed results when her pants began getting baggy around her legs.\nLike many on the various detox plans, she couldn't stomach the all-liquid diet and craved solid food.\nNina said the regimen included taking seven large capsules four times a day.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "There did not appear to be anyone knowledgeable about weight, weight loss, or anything medical consulted for this segment.", "answer": 0}, {"article": "Sorry. The page you requested is not available", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The reporter draws on the journal article and the accompanying editorial.\nSources interviewed include the primary author, one medical expert representing the National Multiple Sclerosis Society and one clinician who treated some patients in the study but was not an author.\nThis is sufficient sourcing.\nIt is worth pointing out here, however, that Genentech and Biogen Idec, makers of Rituxan, are \u201cCorporate Star\u201d supporters of the National Multiple Sclerosis Society.", "answer": 1}, {"article": "After radiation treatment, patients often experience severe, lifelong swallowing, eating, and nutritional issues.\n\u201cAnd while traditional chemoradiation has demonstrated good tumor control and survival rates for patients, too often they encounter unpleasant outcomes that can include difficulty swallowing solid foods, impaired nutrition, aspiration and feeding tube dependence,\u201d said Dr. Burtness.\n\u201cWe found there are some patients have very high cure rates with reduced doses of radiation,\u201d said Barbara Burtness, MD, Professor of Medicine (Medical Oncology), Yale Cancer Center, Disease Research Team Leader for the Head and Neck Cancers Program at Smilow Cancer Hospital, and the chair of the ECOG-ACRIN head and neck committee.\nEligible patients received three courses of induction chemotherapy with the drugs cisplatin, paclitaxel, and cetuximab.\nPatients with good clinical response then received reduced radiation.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release failed to mention any funding source or the presence or absence of a conflict for researchers.\nThe published study notes that the research was supported by\u00a0US Public Health Service grants,\u00a0the National Cancer Institute, National Institutes of Health, and the US Department of Health and Human Services. An author quoted in the release disclosed consulting and other financial relationships with seven pharmaceutical companies but no radiation device manufacturers.", "answer": 0}, {"article": "\u201cBut I wasn\u2019t really doing well,\u201d said Ms. Schomaker, 73.\nFriends thought Anne Schomaker was coping well with her loss, she recalled.\n\u201cI had terrible pangs of sadness and despondency.\n\u201cI had many interests.\u201d She traveled and even tried dating again.\n\u201cThe pain just didn\u2019t go away,\u201d she said.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story includes several sources whose affiliations are well described, including a skeptical voice. There is no obvious conflict of interest, beyond the professional investment that some of these researchers might have in advancing the notion of \u201ccomplicated\u201d grief.", "answer": 1}, {"article": "The researchers noted that thousands of people in this final group were participants in the Women\u2019s Health Initiative, a long-term study sponsored by the National Heart, Lung and Blood Institute in the U.S. Earlier reports based on data gathered by the Women\u2019s Health Initiative found that calcium and vitamin D supplements were associated with a lower risk of fractures, but only for women who took hormone therapy after menopause. To get a clearer picture of the direct link (if any) between supplements and fracture risk, Zhao and his colleagues opted not to include data from women on hormone therapy.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The only source quoted for the article is the study itself. There are no quotes from independent expert sources.", "answer": 0}, {"article": "But at least we know it can be done.\"\nThe results were barely significant on statistical grounds, perplexing for scientific reasons and unanticipated by most researchers.\nThe study cost $105 million, most of it provided by the National Institutes of Health.\nIt is unlikely -- but not impossible -- that any country would consider it effective enough to be used as a public health measure against HIV.\nNevertheless, the first positive result for an AIDS vaccine after two decades of experimentation is being called a milestone.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Interviews with Dr. Fauci of NIH, with one of the investigators, and with an unnamed skeptic.\u00a0 ", "answer": 1}, {"article": "Sigmund Freud often included one of his dogs in psychoanalysis sessions.\nIn other words, people are recognizing that anecdote isn\u2019t enough.\u201d\n\nUsing animals in mental health settings is nothing new.\nCherry-picked positive results also are a problem, as he says happens in promotional materials from the Human-Animal Bond Research Initiative (HABRI).\nMore generally, Serpell said, the popular idea that pets make you happier \u201cis not a harmless distortion.\nAnd that\u2019s just as important.\u201d\n\nFocusing too much on scientific support sometimes feels like a form of \u201cphysics envy,\u201d Beck added, \u201cwhere you try to quantify everything without appreciating it.\u201d\n\nBut there are good reasons for rigorous research on animals and mental health.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "This was a strong point of the story. It cites multiple sources, clearly identifies the affiliation of all sources, and places those affiliations in a context that readers can understand. For example, the story includes input from a source at the Human-Animal Bond Research Initiative (HABRI) \u2014 and explains that HABRI is a pet-industry backed organization that funds research on the topic of therapy animals.", "answer": 1}, {"article": "Doctors who have turned surgery into a popular treatment for obesity are setting their sights on a burgeoning new market: diabetes patients.\n\nA growing amount of research suggests that bariatric surgery, which shrinks the stomach and sometimes reroutes the intestines, has a lasting effect on the most common form of diabetes, and not just because patients lose weight. Studies have found that more than 75% of patients with this type of diabetes who undergo the surgery see their disease disappear. They can go on to live diabetes-free...", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The reporter interviews both supporters and critics of the diabetes surgery. He also makes clear that the surgeons who advocate using bariatric surgery for diabetes have a big financial stake in the issue.\u00a0The published papers he cites all appeared in credible journals. ", "answer": 1}, {"article": "(Reuters) - U.S. health regulators said on Tuesday they approved a stent by Abbott Laboratories that is the first designed to be absorbed into the bloodstream after it is implanted.\nAbsorb\u2019s appeal is that it allows the blood vessel to return to a natural state, free from a permanent metal implant.\nAnalysts have predicted Absorb will gain a market niche but not surpass drug-dispensing metal stents such as Xience in share until longer-term data show more favorable clinical results.\nAbbott plans to roll out the device to about 100 hospitals in the next several months as it trains surgeons on the implant procedure before ramping up sales, said spokesman Jonathon Hamilton.\n\u201cThere are no longer going to be permanent metal implants in the artery.\u201d\n\nAbsorb releases the drug everolimus to combat the growth of scar tissue that can form within a stent and cause the artery to narrow again, the U.S. Food and Drug Administration, which approved the stent, said.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Both scientists quoted in this story are connected in some way to Abbott Labs; one is a (presumably paid) adviser to the company while the other led the company\u2019s clinical trial. \u00a0They are clearly identified.\u00a0 A reader would likely infer, correctly, that development of the new device has been funded by the lab. But had the reporter sought out an independent source or two, the murky nature of long-term effects of the stent might have become more obvious.", "answer": 0}, {"article": "An electromagnetic wave then agitates water molecules in the surrounding tumor tissue, producing friction and heat that eventually destroy the tumor.\nU.S. researchers say the technique certainly shows promise.\nIn a preliminary study, the technique, called microwave ablation, eliminated lung tumors in 19 of 28 patients.\nThe findings were presented here at the annual meeting of the Radiological Society of North America.\nNov. 28, 2011 (Chicago) -- Researchers are using high-energy waves similar to those used to make microwave popcorn to destroy inoperable lung tumors.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes one independent source: American Society of Clinical Oncology spokesman Gregory Masters, MD, a medical oncologist at the Helen F. Graham Cancer Center. More sources could have deepened our understanding of the technique.", "answer": 1}, {"article": "A new study has an intriguing finding: Advanced cancer patients who received early palliative care in conjunction with standard care for their disease not only reported better quality of life, but lived a few months longer than patients who received only standard care.\n\nThe research, published in the New England Journal of Medicine, included 151 patients diagnosed with metastatic non-small-cell lung cancer who were randomly assigned to one of those treatment plans. At 12 weeks, 86% of those who were still alive filled out assessments \u2026", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Although it didn\u2019t include the breadth of perspectives included in some of the other stories about this study,\u00a0this story\u00a0did include an interview with an expert not affiliated with the study\u2013enough for\u00a0a satisfactory.\u00a0Since this source is the past president of American Academy of Hospice and Palliative Medicine\u2013 a professional group that obviously supports increased awareness and use of palliative care\u2013we wish it had also included a comment from someone without these industry ties. \u00a0\u00a0", "answer": 1}, {"article": "That number was the same in younger people who had large waistlines, and even lower in those with metabolic syndrome, a combination of risk factors including belly fat, high blood pressure and high blood sugar.\nLeFevre, a member of the U.S. Preventive Services Task Force, a federally appointed expert panel, said the chances that a polyp turns into cancer is currently a matter of debate.\nAs a result, he said, it is hard to know whether removing polyps in younger people would in turn lower their risk of getting cancer.\nOne gastroenterologist said the results were \u201cimportant\u201d but should not change practice.\n\u201cYou want to make sure that the advantages are going to outweigh the harms,\u201d said the American Cancer Society\u2019s Smith.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes several independent experts who provide very valuable perspectives.", "answer": 1}, {"article": "\u2022 The percentage of days with full asthma control were virtually the same for acetaminophen and ibuprofen: 85.8 and 86.8 percent, respectively.\nWhile the study was modest in size, it was powered to detect any clinically significant differences, more so than past retrospective studies, Phipatanakul notes.\n(The asthma therapies were given in varying order as part of a concurrent randomized trial, making this, in effect, a \"trial within a trial.\")\nThe study enrolled 300 children 1 to 5 years old with mild persistent asthma.\nThe 18-site study should settle a debate that originated when several retrospective studies seemed to indicate that children had exacerbations of their asthma when receiving Tylenol for pain and/or fever.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "Boston Children\u2019s Hospital discloses the fact that the National Institutes of Health and the National Heart, Lung and Blood Institute\u2019s Asthma Network (AsthmaNet) funded the study.\nHowever, no mention is made of the ties several of the researchers have to Pfizer, the maker of Children\u2019s Advil, and to McNeil Consumer Healthcare and Johnson & Johnson, makers of Tylenol.\nNot providing the potential conflicts of interest earns the release a Not Satisfactory rating here.", "answer": 0}, {"article": "The rate was 26 percent lower in counties with screening.\nThe study\u2019s conclusions contrast with those of a report last year by the United States Preventive Services Task Force, an independent group that issues guidelines on cancer screening, questioning the benefit of screening women younger than 50.\nThe study\u2019s authors include Dr. Stephen Duffy, an epidemiologist at the University of London, and Dr. Laszlo Tabar, professor of radiology at the University of Uppsala School of Medicine in Sweden, who have long been advocates of mammography screening.\nThe new study took advantage of circumstances in Sweden, where since 1986 some counties have offered mammograms to women in their 40s and others have not, according to the lead author, Hakan Jonsson, professor of cancer epidemiology at Umea University in Sweden.\nBut their results were greeted with skepticism by some experts who say they may have overestimated the benefit.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "\n\n\nA strong point of this story is the inclusion of comments from several independent experts with a variety of perspectives on the meaning of the latest study results. The story does not mention any potential conflicts of interest, but the researchers did not list any in their journal article.", "answer": 1}, {"article": "Traditionally, patients with leukemia, lymphoma and myeloma have first tried to find an adult bone marrow donor either from a close relative or from a national bone marrow registry.\nAnd patients still must endure months of recovery.\nBut Tirpak's physician, Dr. Mary Laughlin, turned to something deemed medical waste until recently: umbilical cord blood.\nWell worth it, say Mumford and Tirpak, who received her stem cell injection two years ago.\nUntil recently, Tirpak would have faced a death sentence without a bone marrow transplant.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The online story quotes only one physician.\u00a0 Another independent expert might have raised some of the questions that we have raised throughout this review. ", "answer": 0}, {"article": "Philip Gehrman, a Penn clinical psychologist who was senior author, said the study proves that rapid treatment of depression is possible. But more research is needed to figure out why sleep deprivation works. His team is now conducting its own study. He's not hoping to use sleep deprivation as a treatment but thinks that pinpointing what it does to the brain will help doctors develop other, more sustained treatments.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story did not include any independent sources.", "answer": 0}, {"article": "Unlike a heart attack, which happens when blood flow to a portion of the heart is blocked, cardiac arrest occurs when the heart\u2019s electrical system malfunctions, often due to irregular heart rhythms.\nThe study is observational and doesn\u2019t prove bystander CPR increases survival odds, the authors note in Circulation.\nAfter 13 minutes, patients who got CPR at the scene continued to have better survival odds but the difference was no longer statistically meaningful.\n\u201cEarly CPR saves lives, and the lack of CPR efforts from bystanders could result in significantly decreased chances of survival,\u201d said lead study author Dr. Shahzleen Rajan of Copenhagen University Hospital in Denmark.\nResearchers also lacked data on how quickly bystanders intervened after the start of cardiac arrest, which could influence outcomes, the authors note.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes two independent experts whose specific credentials are clearly presented. These sources are cited on the general mechanism of CPR and the importance of starting CPR early. Ideally, they\u2019d also speak to the research itself, providing context on what the general public should know. But given that the story presents the research accurately, and included a discussion of limitations, this is a minor concern here.", "answer": 1}, {"article": "The fibers within the tendons fray.\n\u201cIt\u2019s not insignificant, but it\u2019s not kidney stones.\u201d\n\nSo the question of whether cortisone shots still make sense as a treatment for tendinopathies, especially tennis elbow, depends, Dr. Khan said, on how you choose \u201cto balance short-term pain relief versus the likelihood\u201d of longer-term negative outcomes.\nBut that cautionary experiment and others didn\u2019t slow the ascent of cortisone (also known as corticosteroids).\n\u201cThey change the pain biology in the short term.\u201d But, he said, cortisone shots do \u201cnot heal the structural damage\u201d underlying the pain.\nWhy cortisone shots should slow the healing of tennis elbow is a good question.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "\nThe journalist based the article on two main sources: a systematic review and an editorial from The Lancet. She quoted one of the review authors and one of the editorialists at length.\u00a0 It would have been educational to hear the views of a researcher not involved with either publication. However, this article included a diversity of viewpoints and rates a \u201csatisfactory\u201d on this criterion.\n \n", "answer": 1}, {"article": "But \"that trial is never getting done, nor should it be done,\" Golden said.\nAs to whether circumcision reduces sexual sensitivity, Perera said there's no evidence that it affects sensation when performed on adults.\nNot so, write the Australian researchers, who examined eight studies for a review in the latest issue of the Annals of Family Medicine.\nThe findings come as the American Academy of Pediatrics debates updating its recommendations regarding circumcision among newborns.\nThe highest-quality studies, known as randomized controlled trials, don't report whether infant circumcision affects sensation, she said.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "", "answer": 1}, {"article": "Obstructive sleep apnea (OSA) is marked by interruptions in breathing while asleep; it is common among children with enlarged tonsils or adenoids.\nChildren with sleep apnea can be difficult to rouse, which may cause the bedwetting, said Dr. Dennis Kitsko, an otolaryngologist at the Children's Hospital of Pittsburgh.\nHowever, half of the 417 children in this latest study who had sleep apnea and were bedwetters stopped wetting the bed after they had their tonsils or adenoids removed.\n\"If they haven't seen an ear, nose and throat specialist, see one to see if the child who wets the bed has OSA that can be cured by tonsil or adenoid removal,\" said study author Dr. Yegappan Lakshmanan, chief of pediatric urology at Children's Hospital of Michigan, in Detroit.\n\"About 5 to 7 million children are bedwetters, and the causes fall into three main groups: bladder issues, sleep-related problems and the kidneys,\" he explained.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "This story has more sources than most. It quotes the lead researcher on the study and then four independent sources from a range of specialties.\u00a0They bring some great perspectives to the story and help people understand the connections between different behaviors. \u201cChildren with sleep apnea can be difficult to rouse, which may cause the bedwetting, said Dr. Dennis Kitsko, an otolaryngologist at the Children\u2019s Hospital of Pittsburgh. \u2018But not every child with sleep apnea will wet the bed, and not every bedwetter will have sleep apnea.'\u201d", "answer": 1}, {"article": "He uses an electric mobility scooter for long distances, but he can still walk.\nMany of the clinical trials failed to satisfy the statistical requirement to prove a drug works\u2014at least not for the main outcome the company was looking at.\nBut there\u2019s still a chance the FDA could approve the drug.\nIf they do say no, the Vertins could lose access to the drug that has stabilized their condition.\nSo, if this were any other kind of drug at any other time in FDA history, the FDA\u2019s final answer would be a very predictable no.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Quite a few sources were interviewed for the story. And, all sources are clearly identified, including the CEO of the company that is apparently funding the clinical trials.\nHowever, we do think the story would have been stronger had it tapped the viewpoints of an expert in muscular dystrophy who has no vested interested in the drug receiving approval.", "answer": 1}, {"article": "The FDA is not required to follow the advice of its expert panels, but the agency typically does.\nIn the FDA briefing documents, an agency reviewer recommended approving the drug for treatment of acute coronary syndrome, mostly because trial data showed there was a reduction in cardiovascular death, even though there was also an increased risk of potentially fatal bleeding.\nOf those patients, 136 had bleeding in the brain.\n\"While it is true that these bleeding events typically do not lead to death or irreversible harm, these events may represent the biggest problem for both patients and health care providers if rivaroxaban is approved.\"\n\"However, what is not reflected in the sponsor's analysis are minor bleeding events,\" FDA reviewer Dr. Karen Hicks wrote in the briefing documents.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "No independent source was quoted.", "answer": 0}, {"article": "\u201cOpioid overdose deaths are devastating families and communities, especially in rural areas,\u201d said CDC Director Tom Frieden, M.D., M.P.H.\nDepartment of Health and Human Services Secretary Sylvia M. Burwell has made addressing opioid abuse, dependence, and overdose a priority and work is underway at multiple HHS agencies on this important issue.\nA majority of states have adopted national guidelines that prohibit basic EMS staff from administering the drug as an injection.\nHHS\u2019 Health Resources Services Administration recently released a grant opportunity aimed at reducing opioid overdose deaths in rural communities through funding for communities to purchase naloxone and train health care professionals and emergency medical staff on its use.\n\u201cMany of these deaths can be prevented by improving prescribing practices to prevent opioid addiction, expanding the use of medication-assisted treatment, and increasing use of naloxone for suspected overdoses.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "It\u2019s clear that the release comes from the CDC, and the release links back to the CDC website, which makes it clear for anyone who might not know that the CDC is funded by the federal government (your tax dollars).", "answer": 1}, {"article": "Both the American Heart Association and the World Health Organization recommend getting at least 150 minutes of moderate- to high-intensity physical activity a week for cardiovascular and overall health.\n\u201cThere is good evidence that physical activity can help people recover from depression, though we recommend it be used in addition to the usual treatments we would prescribe for established depression, like medication and counseling,\u201d says Harvey.\nThe study could not prove a cause-and-effect relationship between exercise and the risk of depression, but the authors say it strongly suggests one\u2014especially because they controlled for other potential factors, including age, gender, social support, smoking, drinking and body mass index.\n\u201cOur study takes this a bit further and shows that exercise may also have a role in preventing people developing depression in the first place.\u201d\nIt\u2019s also possible, they add, that exercise may trigger changes in self-esteem, the release of mood-boosting endorphins and the production of certain proteins.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story doesn\u2019t include any content from independent sources.", "answer": 0}, {"article": "Aug. 10, 2011 -- Two of three patients dying of chronic lymphocytic leukemia (CLL) appear cured and a third is in partial remission after infusions of genetically engineered T cells.\nBut the therapy worked vastly better than University of Pennsylvania researchers David L. Porter, MD, Carl H. June, MD, and colleagues had dared to hope.\nThe treatment success came in a pilot study that was only meant to find out whether the treatment was safe, and to determine the right dose to use in later studies.\nThis may be why relatively small infusions of the CAR T cells had such a profound effect.\nWhat's new about the current treatment is the addition of a special signaling molecule called 4-1BB.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Both stories could have used more outside sources. In each case, only one outside source was quoted. In the WebMD case, the outside source was overly effusive. In the Reuters case, the outside source did a better job tempering some of the enthusiasm of the authors with a realistic assessment of the treatment\u2019s prospects.", "answer": 1}, {"article": "Friedman, who is now 70 and lives in Los Angeles, lost 175 pounds.\nSo Friedman opted for a less invasive procedure to make her stomach smaller again.\nAnd research conducted over the past decade suggests it works.\nFriedman kept the weight off for almost 10 years.\nIt's one of several procedures designed to help people maintain the benefits of bariatric surgery.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes an independent expert who provides useful context about this type of surgery. While it clearly meets our standard, the story could have offered a few more details about this source. Is he a bariatric surgeon? Has he used this device? That would give readers a better perspective from which to evaluate his comments about the procedure.", "answer": 1}, {"article": "Parkinson's is not considered an inflammatory disease, he said, adding: \"We might be missing something.\n\"It's intriguing [that the finding applied to] just ibuprofen and not aspirin or acetaminophen or other commonly prescribed medications for inflammation because it implies something more specific to ibuprofen that should be investigated,\" Tagliati said.\nStudy author Dr. Xiang Gao, an instructor and epidemiologist at Harvard Medical School and Brigham and Women's Hospital in Boston, said the findings are important for anyone at increased risk for Parkinson's because most people with the disease eventually become severely disabled.\nDr. Michele Tagliati, an associate professor of neurology and director of the Parkinson's Disease Center at the Mount Sinai School of Medicine in New York City, described the results as somewhat surprising and said they emphasized the need for further study.\nGao said that though the drug levodopa is the current standard treatment for Parkinson's, much more is needed.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "One independent source was quoted.\u00a0 But we\u2019re troubled by the story letting that source get away with saying he would \"definitely discuss ibuprofen use\" with his patients \u2013 because it would be very easy to find other sources who would say it\u2019s far too early to discuss ibuprofen use with their patients.\u00a0 In fact, a MedPageToday.com story stated that the lead researcher himself said \"that it\u2019s too early to make any clinical recommendations based on the observational data, which not only need confirmation in prospective trials but also cannot prove causality.\"", "answer": 1}, {"article": "[Seriously, why does anyone under 18 still have access to a tanning bed?]\nThat said, the agency warned Wednesday that the new drug can cause serious side effects, including trouble swallowing or nerve damage to the jaw that can result in an uneven smile or muscle weakness in the face.\nPatients can receive as many as 50 injections of the drug in a single treatment, the agency said, with up to six treatments administered no less than a month apart.\nKeith Leonard, chief executive of Kythera, the California-based firm that developed Kybella, said at a conference last month that he believes the new treatment \"can drive a very large market and leave very satisfied patients.\"\nThe FDA warned, however, that the treatment also has the potential to kill other types of cells, such as skin cells, if injected improperly.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story relied almost entirely on a news release and prior comments from representatives of Kythera. It quotes a company official saying the drug\u00a0\u201ccan drive a very large market and leave very satisfied patients.\u201d That seems imbalanced when no independent source is tapped to evaluate the claims.", "answer": 0}, {"article": "His \"tactile imaging system\" capitalizes on the fact that cancerous lumps tend to feel harder and less movable than harmless abnormalities such as fluid-filled cysts or fibrous nodules. The fist-sized, $1,000 machine \u2014 with an elastomer probe, a light, and a camera \u2014 acts like ultrasensitive fingertips. It measures the size, elasticity, and mobility of a breast lump, then a computer program converts the data into a score from 1 to 5, with scores under 2 likely to be benign.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "No independent sources are quoted.\u00a0 The only quotes in the article are from Dr. Won, the engineer who developed the device.", "answer": 0}, {"article": "For more about healthy eating, visit the U.S. Centers for Disease Control and Prevention.\nDr. Sonia Anand, a professor of medicine and epidemiology at McMaster University in Hamilton, Canada, praised the study, saying it's \"reasonable\" to link changes in diet to death rates in this way.\nBut other research has pinpointed a decline in death rates in this century, Wang said.\nChan School of Public Health in Boston, cautioned that it's not time to declare victory in the battle against unhealthy eating.\nThe findings paint a surprising picture of American health.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "As noted, the article would have been stronger if it had quoted more senior authors of the paper and more outside experts, but it does quote one and the quote is strong.", "answer": 1}, {"article": "on Sept. 2.\n\u201cA peripheral T-cell lymphoma patient,\u201d he said, \u201cat first blush will see this therapy as a very good thing.\u201d\n\nAllos, which is still unprofitable, has lost $350 million since its founding in 1992 and failed to win approval of a previous drug.\nMr. Schimmer\u2019s note was entitled \u201cFolotyn Prices High, Reiterate Outperform.\u201d He estimated annual sales of the drug in the United States reaching about $300 million by 2014.\nIn a note to clients in October, Joshua Schimmer, an analyst at Leerink Swann, estimated that a typical treatment would last 3.5 months and cost $126,000, or about $36,000 a month.\nIt says it will give the drug free to uninsured patients who cannot pay for it any other way.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes multiple stakeholders, including experts from the drug manufacturer, a large\u00a0insurance company, and lymphoma researchers. The provide valuable diversity of perspectives on this controversial issue.", "answer": 1}, {"article": "Trials were conducted on nine healthy individuals in a blinded comparative study on absorbable versus fermentable carbohydrates.\nThe findings show the revolutionary gas-sensing capsule developed by researchers at RMIT University in Melbourne, Australia, could surpass breath testing as the benchmark for diagnosing gut disorders, paving the way to solving previously undiagnosed conditions.\nCapsule co-inventor, RMIT's Dr Kyle Berean, said the second human trials have revealed information about gas production in the gut previously masked when measured indirectly through the breath.\nNew trials of a breakthrough swallowable sensor have revealed the device is 3,000 times more accurate than current technology used to diagnose many gut disorders.\nStudy lead and capsule co-inventor Professor Kourosh Kalantar-zadeh said the results showed high sensitivity and signal-to-noise ratio in measuring the concentration of intestinal hydrogen, providing valuable information at the site of intestinal gas production.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "It\u2019s made clear that one of the sources quoted is the capsule co-inventor, and is also the chief technology officer of the company trying to commercialize the capsule.\nHowever, it\u2019s unclear if the second source \u2014 identified as the study lead and a capsule co-inventor \u2014 is also affiliated with the company.", "answer": 1}, {"article": "Traditionally, highly sensitized patients in need of a kidney have languished on waiting lists because it's so hard to find a compatible donor.\nThose patients were all successfully treated with standard anti-rejection drugs, according to the researchers.\nResearchers found that the treatment -- dubbed IdeS -- quickly wiped out the dangerous antibodies, allowing all but one of 25 patients to have a successful transplant.\nFunding for the study came from the company developing IdeS -- Hansa Medical.\nBut the findings mark another step forward for patients like these, according to Jordan, who is medical director of the kidney transplant program at Cedars-Sinai, in Los Angeles.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The article duly discloses that the study was conducted or somehow supported by Hansa Medical, the maker of the enzyme infusion, and quotes at least two experts not involved in the study itself.", "answer": 1}, {"article": "I was absolutely terrified because I saw my mom go through it, and I saw how much pain she was in,\" Barletta says.\nThat's still the standard procedure for the 50,000 Americans who are operated on each year for this problem.\nLaPook notes that it will be a few more years before this procedure is widely available.\n\"I was so happy that I was OK, that I had escaped the open heart,\" Barletta says.\nDr. Saibal Kar performed the innovative procedure on Barletta at Cedars Sinai Hospital in Los Angeles.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The interviewees were all fans and users of the procedure.\u00a0 The range of sources wasn't diverse.\u00a0 \nIt would have been beneficial to have someone comment on the difference between the procedures, the types of conditions that may be most amenable to treatment with the experimental medical device, and some more about patients for whom it might be appropriate to consider use of the device.", "answer": 0}, {"article": "\u201cI am aware of the fact that given our level of ignorance, everything seems simple and straightforward,\u201d he says.\nThat\u2019s because experts believed that once the pancreatic islet cells, the body\u2019s insulin-making factories, were compromised, they couldn\u2019t be made to work again.\nMore work will be needed to confirm what benefit betatrophin might have on diabetic patients before that might be possible, however.\nWhat\u2019s more, they also surmised that only a specialized set of beta cells were equipped to make insulin, and that once diabetes set in, too few of these cells remained to pump out the critical hormone.\n\u201cWe don\u2019t understand the cause of type 2 diabetes, but everyone agrees that having more beta cells is better,\u201d says Douglas Melton, senior author of the paper and co-director of the Harvard Stem Cell Institute.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story features a useful comment from an American Diabetes Association expert (though we wonder how many people will read far enough down the story to see it). Unfortunately,\u00a0the story didn\u2019t mention that the authors of\u00a0the study already have agreements in place to commercialize their research. Here\u2019s how a press release about the study described these relationships: \u201cWorking with Harvard\u2019s Office of Technology Development, Melton and Yi already have a collaborative agreement with Evotec, a German biotech firm that now has 15 scientists working on betatrophin, and the compound has been licensed to Janssen Pharmaceuticals, a Johnson & Johnson company that now, too, has scientists working to move betatrophin toward the clinic.\u201d", "answer": 0}, {"article": "A growing body of evidence suggests that weight-loss surgery is more effective than diet and exercise at getting rid of Type 2 diabetes.\n\nA small but rigorous randomized trial published Wednesday in JAMA Surgery provides the latest evidence showing the superiority of bariatric surgery over lifestyle changes in resolving the chronic condition involving high blood sugar.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The Not Satisfactory rating here doesn\u2019t tell the whole story. The article makes good and broad use of sources, beyond the authors of the research publication. The article has some input from those who point out the need for longer term follow-up. And it does an especially good job of bringing out information about clinical guidelines and how they might change in response to the growing evidence for the benefits of weight loss surgery. Alas, the editorialist quoted at the end of the study, who very enthusiastically endorses wider use of bariatric surgery,\u00a0acknowledged speaking fees from a number of companies who manufacture bypass surgery equipment. The story does not alert readers to this conflict of interest, which triggers an automatic Not Satisfactory rating here.", "answer": 0}, {"article": "WASHINGTON -- A new study shows patients taking the anticlotting drug Plavix along with a type of drug used to block stomach acid have an increased risk of a subsequent hospitalization for heart trouble.\n\nThe study, which is being published in this week's Journal of the American Medical Association, adds to other recent studies that suggest proton pump inhibitors like Aciphex, Nexium, Prevacid and Protonix reduce the effectiveness of Plavix, which is marketed by Bristol-Myers Squibb Co. and Sanofi-Aventis SA.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story included quotes from the lead author of the study and from a drug company representative.\u00a0 We wish the story had included the input of a clinician not connected to the study.\u00a0 However, we give credit because the story noted that one of the researchers received honoraria and research support from two drug companies. \u00a0 ", "answer": 1}, {"article": "Also low are haddock, pollock, flounder and sole, Atlantic croaker, crawfish, catfish, trout, Atlantic mackerel, crab and mullet.\nBut a federal panel has reignited the debate about the benefits and risks of eating tuna and other seafood during pregnancy.\nCurrently fewer than one in five Americans eats the recommended two servings a week of fish.\nIn the report, the panel argues that albacore tuna is a \u201cspecial case.\u201d They noted that even when women ate double the recommended weekly amount of tuna, the benefits far outweighed the risks.\nIn addition to the usual warnings about high mercury fish, Consumer Reports added marlin and orange roughy to the list.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes only three sources. Two of the sources are members of the Dietary Guidelines Advisory Committee, which released the very report they were asked to comment on. One of those two sources is Alice Lichtenstein. While the story tells readers that Alice Lichtenstein is \u201csenior scientist and director of the Cardiovascular Nutrition Laboratory at Tufts University,\u201d it failed to note that she is also the vice chair of the Dietary Guidelines Advisory Committee. The third source is a co-founder of the Mercury Policy Project, which is a longtime advocate for limiting mercury exposure. Input from an outside expert on prenatal or pediatric nutrition would have been great.", "answer": 0}, {"article": "The American Academy of Family Physicians outlines medicines used to treat patients with acute coronary syndrome.\nA study author agreed that for most patients, using the drug with a lower dose of aspirin is usually warranted.\nThe panel's recommendation was based in part on prior findings from this study, called the Platelet Inhibition and Patient Outcomes (PLATO) trial.\n\"A higher aspirin dose (325 mg versus 81 mg) increases the risk of bleeding without increasing the efficacy of the drug.\"\nIn this latest analysis of PLATO findings, researchers found that patients who took Brilinta with low-dose aspirin were 16 percent less likely than those who took Plavix with low-dose aspirin to have a heart attack or stroke, or to die within a year.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Our biggest bone to pick with the story is its failure to mention that the study was funded by the maker of drug. Keep in mind that Brilinta is going up against Plavix, shortlisted\u00a0with the best-selling drugs on the planet, and at US sites of PLATO, Plavix \u201cwon\u201d (kind of). With FDA approval influenced by the results of this PLATO follow-up, AstraZeneca\u2019s funding was a pretty important conflict of interest to disclose.  One independent source was cited, Dr. Berger. Further sources may have revealed more of the history and controversy in the field. In the discussion at the AHA conference where this new study was announced, at least one panelist said he thought the results were \u201cspurious,\u201d emphasizing the study\u2019s conclusion that the result could have been due to chance.", "answer": 0}, {"article": "Nov. 18, 2012 -- Researchers say they've been able to use nanoparticles to stop multiple sclerosis (MS) in mice that are bred to have the disease.\nWhat remains to be seen is whether the researchers have picked the right proteins that might turn off the disease in humans, he says.\n\u201cThis technology could be very effective,\u201d says Timothy Coetzee, PhD, chief research officer for the National Multiple Sclerosis Society.\n\u201cWill these peptides actually induce tolerance in people?\nThe particles are about 200 times smaller than the thickness of a human hair.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story relies mostly on the two lead researchers on the project, but it does bring in some important context from the chief researcher for the National Multiple Sclerosis Society, who provides a cautious tone at the start of the story. It also explains how the study was funded.", "answer": 1}, {"article": "Because this important step is out of the way in advance, it completely changes the patient\u2019s day of surgery experience.\u201d\n\nRadar can target abnormality within 1 mm, sparing more healthy tissue\n\nUnlike mastectomy, which treats breast cancer by removing an entire breast, lumpectomy surgery \u2014 also known as breast-conserving surgery \u2014 is used to remove only the tumor and a small amount of tissue surrounding the tumor.\n\u201cUntil now, a patient would go to the imaging center to have the thin wire precisely placed in the breast.\nThe SAVI SCOUT Radar Localization System helps to decrease the time a woman is in the operating room, increase the success rates of lesion removal and reduce the amount of healthy breast tissue that is removed during the procedure.\n\u201cWhen the marker was inserted near the lump, it was similar to a biopsy.\n\u201cWhen Madrigrano told me about it, I thought it was an ingenious idea and I\u2019m glad it was developed,\u201d said Nancy Morrissey, who underwent lumpectomy surgery at Rush in July using the SAVI SCOUT technology.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "Since there\u2019s no study involved we rate the first half of this criterion (Funding Sources) Not Applicable. But the news release is silent on potential conflicts of interest either institutionally or with individuals mentioned. Is Dr. Madrigrano, who speaks favorably about the device, a paid consultant to the company that makes it? We would have liked some information on any institutional or individual potential (or lack thereof) for conflict of interest.", "answer": 0}, {"article": "Watch Sanjay Gupta MD Saturday at 4:30pm and Sunday at 7:30am ET.\nAgatston says relatively new imaging tests give real-time pictures showing whether plaque is building up in key blood vessels, alerting doctor and patient to an increased risk of a potentially deadly heart attack.\nAgatston thinks the coronary calcium scan should be routinely scheduled at age 50, like a colonoscopy, or earlier for people with family histories of heart disease.\n(Agatston does not make any money from the coronary calcium scan.)\nA calcium score would answer that question, she says.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Considering that the United States Preventive Service Task Force and other major medical groups do not recommend coronary calcium scoring or carotid ultrasound screening for most people, this story should have included comments from someone explaining that consensus opinion.", "answer": 0}, {"article": ".\nThe findings bordered on statistical significance, suggesting that future clinical trials with a greater number of patients are needed to show similar benefits.\nThe study was funded by the Arline and Henry Gluck Foundation.\nThat is why patients need a CT scan to confirm the type of stroke before receiving tPA.\nNour's team used data from Berlin's PHANTOM-S study, which took place from 2011 to 2015 and included 427 participants (median age 72) which were compared to 505 patients who received conventional care with in-hospital clot busting.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release explains the funding source and points to the abstract, which notes that one of the authors received a modest grant from a pharmaceutical company for a clinical trial for a clot-busting drug.", "answer": 1}, {"article": "An experimental drug has proved effective at treating an aggressive form of breast cancer in patients who aren't responding to the widely used drug Herceptin, giving hope to women with otherwise limited treatment options, said drug maker GlaxoSmithKline PLC, presenting the results Saturday at the American Society of Clinical Oncology meeting in Atlanta.\n\nWhen taken with a standard chemotherapy treatment in a clinical study, the new drug, Tykerb nearly doubled the time to 8.5 months before the average patient's breast cancer...", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story relies solely on sources associated with GlaxoSmithKline. The lead author of the study is cited, however, the study was sponsored by this drug manufacturer. Additional oncology researchers are needed for perspective on the results of lapatinib in metastatic breast cancer patients. ", "answer": 0}, {"article": "We have to really ask the question: 'How low do you go?'\nAlthough the reason for the increased risk remains a mystery, Nabel and other experts stressed that the benefits of blood sugar control have been well established for diabetics and said patients should not make any changes in their care without consulting their doctors.\nBut the findings cast doubt on a major hope about diabetes treatment -- that pushing levels below current targets would be beneficial -- and would force experts to rethink how to treat one of the nation's leading health problems.\nBecause some of the patients were taking the drug Avandia, which has been the focus of concern that it might increase the risk of heart attacks, the researchers specifically examined whether that was a factor.\nOfficials defended the study, saying previous research had suggested that intensive blood sugar lowering would be beneficial.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Comments from interviews with several individuals knowledgeable about the trial (i.e. cardiologist, people at the National Heart, Lung and Blood Institute) were included in this story.\u00a0 ", "answer": 1}, {"article": "Guidelines also suggest that pregnant women not drink more than two cups a day.\nI can\u2019t think of any other product that has this much positive epidemiologic evidence going for it.\nI grant you that pretty much none of the research I\u2019m citing above contains randomized controlled trials.\nIt\u2019s important to remember that we usually conduct those trials to see if what we are observing in epidemiologic studies holds up.\nMost of us aren\u2019t drinking coffee because we think it will protect us, though.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "An independent expert would have added valuable context here, but no such voice is provided.\nAre studies of coffee consumption which find themselves as part of meta-analyses of coffee consumption funded by, tied to, or otherwise linked to Big Coffee in any way that suggests commercial biases in this research? \u00a0We don\u2019t know, and we don\u2019t learn about any such conflicts of interest in the story. Is it a conflict of interest if the reporter, plus most of the researchers and meta-analyzers are routine, habitual coffee consumers?", "answer": 0}, {"article": "Allergan Inc. said that two large human tests of its Botox drug, best known for smoothing wrinkles, showed that periodic injections prevent headaches in adults who suffer from chronic migraines.\n\nEven though details of the study weren't released, the announcement, which surprised many physicians and investors, sent Allergan's shares soaring 11%, or $5.95, to $60.53 at 4 p.m. in New York Stock Exchange composite trading. Botox has been used to treat severe headaches for many years, but some researchers have long been skeptical...", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes multiple experts who provide valuable persepctive.", "answer": 1}, {"article": "The apolipoprotein gene is inherited from each parent and when a patient inherits the ApoE4 variant from one parent they have a three times greater risk of developing Alzheimer's disease, whereas a patient who inherits ApoE4 from both parents is eight-to-12 times more likely to develop the disease.\n\"This type of testing is important in our quest to understand and diagnose Alzheimer's and empower patients to understand risks, consider medication, and even make early lifestyle changes.\"\n\"This fast, accurate testing will allow doctors and patients to make more informed choices earlier to potentially slow the possible progress of Alzheimer's.\"\nResearchers from Randox Laboratories collaborated with research colleagues at the Medical University of Vienna and found that results from the two tests were in 100% agreement.\n\"Higher FT4 or TSH Below the Normal Range are Associated with an Increased Risk of Dementia: a Meta-analysis of 10 Studies\" (A-180)\n\nSession Information \n\nRegistration for the AACC Annual Scientific Meeting is free for members of the media.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release doesn\u2019t say who funded the research or whether there were any financial arrangements, only that \u201cResearchers from Randox Laboratories collaborated with research colleagues at the Medical University of Vienna.\u201d", "answer": 0}, {"article": "\"If you have your choice, you want to get poked with a needle or you want to try this?\nNow, Gomaa's lab is looking beyond the flu vaccine.\nGomaa's hope is that vaccine patches will cost less than vaccinations do now.\nAnd the patch can be administered by people who aren't trained health professionals.\nA number of the people in the flu patch study applied it to themselves.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The article mentions funders for all of the efforts described. But there is no independent source\u2013everyone in the story\u00a0seems to be connected to a commercial product.", "answer": 0}, {"article": "Behavioral counseling is widely recommended, with medication, to help smokers quit.\nThe findings are at odds with clinical trials, Connolly says.\nBetter strategies are needed to prevent relapse, he tells WebMD.\nThe results of the new study are published online in Tobacco Control.\nSmoking cessation experts and a maker of nicotine replacement therapies took issue with the findings.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "We give the story a pass here because it includes one independent source with good perspective on both the study\u2019s strengths and drawbacks. Half of the people quoted in the story, though, either work for Glaxo or receive funding from Glaxo.", "answer": 1}, {"article": "Researchers at Italy's Institute of Neuroscience injected rats and mice with botulinum neurotoxin A in doses comparable to those used in people.\nYes, there was some evidence the toxin slipped into the bloodstream or the lymph system, but Botox in the bloodstream cannot enter the brain, says its manufacturer.\nA big reason Botox and its cousins, such as Myobloc, were OK'd was that preclinical testing showed that after being injected, they did not travel along the body's highways\u2014nerve cells\u2014to the brain and spinal cord.\nBotox's manufacturer, Allergan, thinks those older studies are more credible.\n\"This study is not conclusive,\" says spokesperson Cathy Taylor, \"and other published studies using botulinum toxin type A contradict these findings.\"\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story included interview material with the author of the rodent study and an excerpt from a comment made by a company spokesperson. \u00a0It should have included comments from independent experts about medical use of botulinum toxin in peple to provide insight into what the compound does, how it works, and the concerns about its use.\u00a0", "answer": 0}, {"article": "All of these study participants \u2014 largely people in their 70s, all with a diagnosis of either \"mild cognitive impairment\" or atypical dementia \u2014 are living with the unconfirmed suspicion that they have Alzheimer's. The study is underwritten by the Centers for Medicare & Medicaid Services and the Alzheimer's Assn. It set out to find out whether knowing \u2014 getting the costly test that would offer either confirmation or reprieve \u2014 would change the way that patients with cognitive troubles are treated, or the way that they plan their lives.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The one expert source quoted is chief scientific offer at the Alzheimer\u2019s Association, which ran the study. Readers would have benefitted from hearing a perspective from an expert or researcher who was not involved with the study.", "answer": 0}, {"article": "Hormone use plummetted, but women who had been using the drugs were left to wonder whether they were still at risk.\nIn fact, the women who took the hormone ended up being at somewhat higher risk for fractures.\nBut the Women\u2019s Health Initiative stunned doctors and women when researchers reported that the risks of the hormones outweighed any benefits.\nThere\u2019s some good news and some bad news for women who took estrogen to help them get through menopause until the health risks of taking the hormone were discovered.\nThe women had taken estrogen for about six years.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "We\u2019ll give the story the benefit of the doubt here, as it at least cited an accompanying editorial \u2013 although, as noted in the \u201cevidence\u201d criterion above, the NY\u00a0Times did a better job in eliciting clear quotes about context from its sources. ", "answer": 1}, {"article": "Highlighting the significance of the findings, the study\u2019s senior author, George A. Macones, MD, the Mitchell and Elaine Yanow Professor and head of the Department of Obstetrics and Gynecology, said, \u201cThis study is a tremendous addition to the literature on preventing surgical-site infections after cesarean.\nBut according to Tuuli, the unique circumstances of a C-section \u2014 that bacteria come from both skin and vagina and that a woman\u2019s immune system is altered during pregnancy \u2014 mean the results of these studies may not apply.\nThe investigators pointed out that all other standard procedures for reducing the risk of infection after surgery, including giving preventive antibiotics beforehand, were the same in both groups.\nThe researchers argue that the evidence is strong enough to change standard skin-prep practices for C-sections.\nOf 575 patients who randomly received the iodine-alcohol combination, 42 developed a surgical-site infection.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release clearly states the funding sources. There were no apparent conflicts.", "answer": 1}, {"article": "According to the National Center for Health Statistics, an estimated 25.3 million Americans, or 11.2 percent of U.S. adults, experience chronic pain.\nSo it makes sense that Jay jumped at the chance to experience long-term pain relief with the help of a spinal-cord stimulator.\nJay says she was lucky: Her insurance covered much of the six-figure bill for the procedure.\nIn an article on Popular Science\u2019s website, Jay writes about her experience with pain and the next-generation way she\u2019s finding relief.\nA next-generation implant deep in Jay\u2019s back stimulates her spinal cord, overriding her body\u2019s pain signals to give her some relief from the back pain that has plagued her for years.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "There were no independent sources quoted in the story, which was a weakness.\nIn the Popular Science column, Jay said she has a \u201cnew part-time job advocating for people in chronic pain,\u201d but not disclose who is paying her. The Washington Post story did not mention that potential conflict of interest.", "answer": 0}, {"article": "\u201cIt is further proof that aspirin is, by a long way, the most amazing drug in the world,\u201d he said.\nPeter Elwood, an expert on aspirin from Cardiff University\u2019s medical school who was not involved in this study, described aspirin as \u201ca remarkable drug.\u201d\n\n\u201cThis risk of a bleed is so small compared to the benefits,\u201d he told reporters.\nThe researchers added, however, that treatment with aspirin during the trials lasted for only for between four and eight years on average, so the effects on risk of deaths due to cancer may underestimate possible results of longer-term treatment.\nThe findings will fuel an already intense debate about the merits of taking aspirin, which increases the risk of bleeding in the stomach to around one patient in every thousand per year.\nAlastair Watson, professor of translational medicine at the University of East Anglia, said the study was an important step in scientists\u2019 understanding of how to prevent cancer.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Technically, this story meets a strict interpretation of the first part of this criterion by including independent experts, even as it grossly violates the spirit. All of the comments are from cheerleaders for aspirin. Experts with a different perspective are left out.\nThe story also fails to report the consulting relationships that some of the study authors have had with pharmaceutical companies.", "answer": 0}, {"article": "Chronic rhinosinusitis (CRS) affects a sizable minority -- 14 percent to 16 percent -- of U.S. residents.\nThis second finding is probably explained by the fact that people going for second or further surgeries were probably sicker to begin with, Josephson said.\n\"These were patients who have chronic sinusitis so, by definition, they have at least three months of symptoms and they have evidence of an ongoing inflammation or infection of their nose and sinuses on either a CT scan or an examination of the nose and sinuses,\" Smith said.\nThe condition, marked by symptoms such as sinus pain and pressure, headache, stuffy nose and sneezing, can compromise quality of life more than even congestive heart failure, back pain or chronic obstructive pulmonary disease, the study authors said.\nFRIDAY, Jan. 1, 2010 (HealthDay News) -- Three-quarters of patients undergoing surgery for stubborn sinusitis saw significant improvements in their quality of life, new research shows.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "", "answer": 1}, {"article": "Compare that with a decrease of about 7 mg/dL for the low-fat diet, and about a 8 mg/dl drop from the moderate-fat diet.\nIt was also supported by a grant from the Hass Avocado Board, an industry group that the researchers say had no role in the design of the study or the interpretation of the data.\nTo put the difference in perspective, the avocado diet decreased LDL cholesterol about 14 milligrams per deciliter of blood.\n\"I was surprised to see the added benefit [of the avocado],\" Penny Kris-Etherton, a nutrition scientist at Penn State and the lead author of the study, tells us.\"\nOne of the moderately high-fat diets included a daily serving of one avocado.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story relies entirely on one source, who was an author of the study. It would have been good to get additional input from other experts in the field. However, the story not only makes clear that the study was partially funded by an avocado industry organization, but discusses the issue at length.", "answer": 0}, {"article": "One in six American adults lives with high cholesterol, and millions have trouble getting it under control, according to the Centers for Disease Control and Prevention.\nIn an editorial published along with the study, experts note that although the results are promising, more long-term research is needed to make definitive conclusions about the drug.\nThe results, published in the Annals of Internal Medicine, also show that the drugs have a significant effect on reducing heart attacks and overall mortality.\nResearchers analyzed 24 randomized control trials to assess the efficacy and safety of the new drugs, called PCSK9 antibodies, in adults with high cholesterol levels.\nOthers have such high cholesterol that taking statins alone is not enough.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes Seth Martin of Johns Hopkins School of Medicine, who is one of the authors of an accompanying editorial in the same journal. We salute the quote from someone independent of the study and who appears to have no conflict of interest \u2014 but wish he had been identified better. Readers can\u2019t tell who he is from the story itself.", "answer": 1}, {"article": "In the Swiss research, animals took a drug that dissolved a barrier around the part of the brain where mammals store their fear memories. Afterward, they stopped being afraid of noises that were linked to electric shocks, which meant their bad memories had been erased, according to the Mail. Human brains, explains NYU neuroscience Prof. Joseph LeDoux, could actually \"overwrite\" memories with happier thoughts if the medication is developed for people, according to the Daily Mail.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "This story provided comments from two independent sources, including a neurologist and a neuroscientist; however, they contributed only hypothetical statements. Perhaps commentary from someone in the mental health profession would have been useful. Additionally, the story may have also mentioned that this research took place in an institute associated with the pharmaceutical company, Novartis. ", "answer": 1}, {"article": "Uridine, which is produced by the liver and kidneys, is also found in some foods as a part of RNA, which helps make protein in the body.\nTo be effective, all three compounds must be given together, the researchers said.\nIn addition, medical foods for Alzheimer's most likely won't be covered by insurance, he said.\nIf it appears to have a positive effect, then it may be something that could benefit patients even before definitive symptoms of Alzheimer's appear, Wurtman said.\nAnd, even then, consumers should exercise caution, said William Thies, vice president for medical and scientific affairs at the Alzheimer's Association.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The Alzheimer\u2019s Association spokesman added some needed perspective. Manufacturer support for the study, and MIT\u2019s patent on the product, were disclosed. It would have been better to additionally have a scientist who studies nutrition and neurodegenerative disease comment on the study.", "answer": 1}, {"article": ".\nThe drug also proved to be highly selective, meaning it hit the intended targets inside the body and did not cause troubling side effects.\nThe drug was pulled from the market in 1997, costing Wyeth millions of dollars.\nIf approved, lorcaserin would be Arena's first marketable product.\nThe trial looked at the effects of three dose levels of the drug.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "There were no sources of information quoted that were independent of the study or the company developing the drug.", "answer": 0}, {"article": "In macular edema, fluid from those damaged vessels leaks into the macula, the part of the retina that is responsible for the straight-ahead vision important for driving, recognizing faces and reading.\nHe said treatment with Lucentis in the clinical trial virtually eliminated those incidents.\nThe steroid treatment did not improve eyesight more than laser therapy alone and caused side effects.\nDr. Neil M. Bressler of Johns Hopkins University, the chairman of the group that conducted the trial, said a two-line improvement in vision would allow some people to read normal-size print or to drive again.\nAbout 1 percent of those getting Lucentis injections suffered an inflammation of the eye from an infection.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "\u00a0Several experts in the field were quoted in this story.", "answer": 1}, {"article": "\u201cC.\nBut most importantly, the study found no difference in effectiveness between the two therapies.\nThough the procedures were done in a Canadian hospital, the FMTs delivered by colonoscopy cost nearly $500 USD more than the capsules, which cost about $300.\nThough physicians think they know how FMTs work, it remains somewhat mysterious.\nKao is one of the authors of the paper and a gastroenterologist at the University of Alberta.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story does include comments from an independent source unaffiliated with the research. But, it doesn\u2019t specify that the source has received research money from a drug company that\u2019s developing microbiome drugs.", "answer": 0}, {"article": "According to the U.S. National Eye Institute, DME occurs when fluid leaks into the center of the macula, the portion of the eye dedicated to sharp, straight-ahead vision.\nThe American Academy of Ophthalmology will review the study findings and make recommendations on whether Lucentis plus laser treatment should be the preferred treatment for a large number of patients with DME.\nThe study, published online in the journal Ophthalmology, was conducted by the Diabetic Retinopathy Clinical Research (DRCR) Network.\nThe results of the new study \"appear to be applicable to most people who have DME in the center of the macula with some vision loss, whether the person has type 1 or type 2 diabetes, is old or young, or is a woman or a man,\" Dr. Neil M. Bressler, chair of the DRCR Network and chief of the retina division, Wilmer Eye Institute, at Johns Hopkins University School of Medicine, said in a news release.\nThis is a \"seminal\" study,\" added Dr. George A. Williams, a board member of the American Academy of Ophthalmology and chair of the ophthalmology department at Oakland University William Beaumont School of Medicine.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Quotes come directly from an American Academy of Opthalmology news release.\u00a0 No discussion of whether either of the quoted experts has financial ties to the company making the drug \u2013 but one of them reported in the study that he had ties to the manufacturer. ", "answer": 0}, {"article": "Lower disk herniation results when the insulating disks that sit between spinal vertebrae tear open, allowing jelly-like material to protrude and exert pressure on surrounding nerve roots.\nHe noted that because \"the majority of people with back pain improve with time and exercise alone,\" it remains an open question as to whether the pRF procedure really cured the condition.\n\"Steroid injections are effective only in portion of the patients, and generally require more sessions,\" he noted.\nThe therapy is not new, having first received U.S. Food and Drug Administration approval in the 1980s.\n\"Best case, I think [pRF] could be an option for people if they [have already] failed therapy and medication,\" said Park.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Laudably, the story contains cautionary comments from a physician who was not involved with the study. He points out that most people with back pain \u201cimprove with time and exercise alone,\u201d and \u201cit remains an open question as to whether the pRF procedure really cured the condition.\u201d\nWe wish some of the cautions had been placed higher in the story.\nThe story did not mention conflicts of interest, and we could not find any that the authors have disclosed.", "answer": 1}, {"article": "But researchers controlled for these and many other factors, and found that compared with women who ate no walnuts, those who consumed 8 ounces of walnuts or more a month reduced their risk for Type 2 diabetes by 24 percent.\nWalnuts may have some unique benefits.\u201d\n\nThe study was supported with grants from the National Institutes of Health and the California Walnut Commission.\nThe scientists, writing in the April issue of The Journal of Nutrition, used dietary and health data on 138,000 women participating in a large continuing study of women\u2019s health.\n\u201cThere\u2019s been a lot of research on nuts in general in relation to cardiovascular health,\u201d said the senior author, Dr. Frank B. Hu, a professor of medicine at Harvard.\nBeginning in 1999 they collected data on walnut consumption, and followed the women for the next 10 years.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "No independent source was quoted \u2013 only the author of the study was quoted.\u00a0 The story did note that the study was partially funded by the California Walnut Commission. It did not mention that the researcher quoted in the story has received funding support from that commission.", "answer": 0}, {"article": "Subsequently, a clinician will help a patient learn to slow down or speed up those brain waves, through a process known as operant conditioning.\nDr. Norman Doidge, a psychiatrist at the Center for Psychoanalytic Training and Research at Columbia and the author of \u201cThe Brain That Changes Itself\u201d (Viking, 2007), said he considered neurofeedback \u201ca powerful stabilizer of the brain.\u201d Practitioners make even more enthusiastic claims.\nThe treatment is also gaining attention from mainstream researchers, including some former skeptics.\nThe findings prompted a boomlet of interest in which clinicians of varying degrees of respectability jumped into the field, making many unsupported claims about seeming miracle cures and tainting the treatment\u2019s reputation among academic experts.\nThese issues, they say, can be represented on a \u201cbrain map,\u201d the initial EEG readings that serve as a guide for treatment.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "\u00a0The story included quotes from advocates as well as skeptics about benefit to be obtained through neurofeedback treatment.", "answer": 1}, {"article": "Niki Munk, an assistant professor of health sciences in the School of Health and Rehabilitation Sciences at Indiana University-Purdue University Indianapolis and one of the co-first authors of the study, said that the study's findings are important, given the large number of people who suffer low back pain in the U.S.\n\nLow back pain leads all disorders in years lost to disability in the U.S.\nAdditional investigation is needed to replicate the results of the initial study and to conduct a cost-benefit analysis of massage therapy, Munk said.\nMore than 50 percent of those who participated in the study experienced clinically meaningful improvements in their low back pain with disability, according to Munk.\nWhile the study results are promising, much more work needs to be done, Munk said: \"The fact of the matter is that chronic lower back pain is very complex and often requires a maintenance-type approach versus a short-term intervention option.\"\nIn this study, patients were referred by a physician to a massage therapist.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release does not give us any information about who funded the study. We should be told who funded the study and if there are any conflicts of interest for the authors or their institutions.", "answer": 0}, {"article": "However, relatively little research has been conducted into ketamine's antidepressant effects in adolescents.\nJames Stone, a clinical senior lecturer from the Institute of Psychiatry, Psychology and Neuroscience at King's College London, who was not involved in the study, told Newsweek that there is \"a lot of potential for the use of ketamine as a second or third line antidepressant where other treatments have failed.\"\nFive of the participants met the criteria for clinical response and remission.\nThe study serves to point out the need for further, rigorous, study designed to answer the many questions that remain about ketamine for TRD, such as optimal dosing and route of administration, dosing interval and treatment length, and long-term effects\u2014just to name a few.\"\nHowever, they note that the study was limited by its small sample size, so future research will be needed to confirm these results.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quoted a researcher unaffiliated with this study.\u00a0 We could find no conflicts of interest.", "answer": 1}, {"article": "In 2008, Medicare paid for 480,000 injections of Avastin to treat macular degeneration and 337,000 injections of Lucentis, according to a study led by Dr. Philip Rosenfeld of the University of Miami.\nIf this finding is considered valid, it could render the results of the National Eye Institute trial somewhat moot by raising safety questions about Avastin.\nHowever, experts say that with only 1,200 patients, the trial will be able to detect only major differences in safety.\nYet Medicare paid only $20 million for the Avastin compared to $537 million for the smaller number of Lucentis injections.\nSales of the drug for each company were about $1.5 billion last year.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "At best, the blog interviewed two NEI\u00a0study investigators and one seemingly independent source to comment on the Genentech study. That doesn\u2019t clear the bar for this criterion.\nIt\u2019s good to get the conflicts of interest for the study designers, but the types, number, and attribution of sources is inadequate, especially given the pre-release nature of the study results. We understand that the two sources had to remain anonymous, but that\u2019s because they were sworn to secrecy. They broke that oath to get the word out a day before the NEJM peer-reviewed publication. One has to wonder, was that truly a service to readers to discuss the results without discussing results, to summarize the message without peer review, to give us opinions without stating conflicts of interest? Especially since the sources disagreed on some aspects? For 24 hours?\n\n \nNo sources were identified. The closest we get is one \u201cretina specialist.\u201d We have no way of evaluating the lenses through which we\u2019re given much of the information.", "answer": 0}, {"article": "Allergy shots may be used for hay fever when antihistamines and other allergy medications do not control a person\u2019s symptoms adequately, or for people who want to reduce their reliance on medication.\nIn addition, the long-term effectiveness of the grass-pollen tablets is not yet fully clear.\nDr. Harold Nelson, an allergist at National Jewish Health in Denver, said that the body of evidence indicates that sublingual immunotherapy beats antihistamines and other medications used to control hay fever symptoms.\nNo sublingual immunotherapy products have yet been approved in the United States, however.\nLike allergy shots, the oral immunotherapy takes time.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "1clip_filelist.xml\"/>1clip_themedata.thmx\"/>1clip_colorschememapping.xml\"/>\n\n\n\n \nThe story includes an interview with an allergist not affiliated with the research.\u00a0 \n", "answer": 1}, {"article": "Normally, cells in the pancreas work to release insulin, a hormone that can process sugar and either send it to cells that need it for energy or store it as fat for future energy needs.\nAll of the people had been diagnosed with type 2 diabetes in the six years preceding the study.\nThe current study takes that work a step further and shows that it\u2019s possible to actually reverse the disease in people who have been diagnosed.\nHe says that it\u2019s critical to discuss from the start \u2014 when people are diagnosed with diabetes \u2014 the possibility of using diet and weight loss to treat their disease.\nThat points to an important lesson that Taylor hopes doctors and patients will learn from the results.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes a study author but no other sources. We think readers deserve to hear from experts not involved with the study at hand to provide context about the findings.", "answer": 0}, {"article": "\n\u2022 People who have had Type 2 diabetes for up to 10 years can reverse their condition\n\nA new study from Newcastle University has shown that people who reverse their diabetes and then keep their weight down remain free of diabetes.\nIn fact, after 6 months a thirteenth patient had reversed their diabetes.\nThis caused international interest, but the study was very short as it was only eight weeks and the question remained whether the diabetes would stay away.\nThe group included many people with longer duration diabetes, defined as more than 8 years and ranging up to 23 years.\nA larger trial involving 280 patients is already underway.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release does identify multiple funding sources and there is no suggestion of any conflict of interest.", "answer": 1}, {"article": "I believe!!!\"\nThat's the paradox of products such as POM, Silverglade says: The health claims on these products strain the imagination, yet studies have repeatedly shown that health claims sell food.\nThe bottom line is that consumers shouldn't believe everything they read on labels.\nAs long as consumers limit themselves to 8-ounce servings and products with no added sugar, juice can be an excellent source of vitamins and other nutrients, Gans says.\nHealth.com: 14 health products you probably don't need\n\nIffy health claims don't mean that products like pomegranate juice should be avoided at all costs, says Keri Gans, R.D., a spokesperson for the American Dietetic Association.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The diversity of voices in this story is a strong point. We hear from consumer advocates, industry and independent researchers, as well nutrition experts. One quibble is that comments from the industry-funded researchers are relegated to the very end of the story and they are made to sound like shills for POM. There\u2019s nothing inherently wrong with industry-funded research, and these researchers can\u2019t necessarily be held responsible for how the funding company\u00a0portrays\u00a0their findings. Whether pomegranate juice\u00a0has health benefits is a question worth exploring; the problems arise\u00a0when companies\u00a0oversell or\u00a0distort the\u00a0results.", "answer": 1}, {"article": ".\nResults of the human study showed that imaging was effective for the evaluation of metastatic prostate cancer, and subsequent therapy resulted in a drop in prostate-specific antigen levels from 38.0 to 4.6 nanograms per milliliter.\nThis new radionuclide drug shows strong binding to the protein PSMA and is readily and safely taken up by malignant PSMA-positive tumors.\nPositive response to therapy was verified via combined PET and computed tomography (PET/CT), a hybrid imaging system that shows both functional and structural aspects of the body.\nPSMA-617 could represent a watershed moment for prostate cancer theranostics.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "There is no mention of funding for this work, so it is difficult to determine if there is any conflict of interest.\u00a0 Funding is listed in the abstract and fairly clearly shows that there is no conflict of interest, but that is impossible to tell from the release.", "answer": 0}, {"article": "At week 40, for example, 81 percent of patients taking a 200-mg dose of guselkumab had a score of 0 or 1, compared to 49 percent of patients taking adalimumab.\n\"Research like this study is leading to a series of new medications that promise high levels of response for an increasing number of patients,\" said first author Kenneth Gordon, MD, professor in Dermatology.\nThis study was supported by Janssen Research and Development, the manufacturer of guselkumab.\nThe disease affects nearly 3 percent of the world's population, according to the World Psoriasis Day consortium, but about half of all patients with psoriasis do not get any treatment, Dr. Gordon said.\nIn the study, published in the New England Journal of Medicine, investigators compared guselkumab to adalimumab, the most common medication currently used to treat psoriasis.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "Although the release clearly notes that the study was funded by the company that manufactures guselkumab, and that the study\u2019s lead author is a former paid consultant for the company, it fails to tell readers that the company was actively involved in the study. The journal article points out that Janssen Research and Development collected and analyzed the data. What\u2019s more, \u201cAll the authors collaborated on writing the manuscript, with the assistance of professional medical writers employed by Janssen, and made the decision to submit the manuscript for publication.\u201d That intimate level of involvement should have been made clear in the release.", "answer": 0}, {"article": "Why Biogen is breathing a sigh of relief with the latest Alzheimer\u2019s data\n\nWe already know Eli Lilly\u2019s big bet on Alzheimer\u2019s disease didn\u2019t work. But a deep dive into just how it failed has provided a bit of encouragement to Biogen and the many companies still hoping to succeed where their rival fell short.\n\nLilly\u2019s treatment, solanezumab, had no significant effect on the buildup of toxic brain plaques believed by many to be responsible for Alzheimer\u2019s neuron-destroying effects. The company had already disclosed that the treatment failed to improve patients\u2019 cognition and function, but the new data, released Thursday night, shed some important light on the underlying biology.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story had no independent sources. It also didn\u2019t disclose the conflict of interest of Dr. Paul Aisen, who\u00a0has received money from multiple drug companies, including the ones discussed in this piece.", "answer": 0}, {"article": "A capsule of Probiotic Immunity from New Chapter Inc., based in Brattleboro, Vt., contains 1 billion each of 10 different organisms, including Streptococcus salivarius subsp. thermophilus and Lactobacillus acidophilus, two species of bacteria often found in yogurt. Other ingredients include herbs such as cumin, ginger and spinach. Users are instructed to take two capsules each day, preferably one in the morning and one in the evening, on an empty stomach. You can buy a bottle of 90 capsules for about $20 at many health food stores.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Independent sources contributed perspectives to this story.", "answer": 1}, {"article": "Research has shown that giving statins to patients who already have Alzheimer's does not seem to help.\nSince cholesterol is part of the tell-tale plaques on the brains of Alzheimer's patients, it made sense to think that statins might help.\nAnd despite this study, there is not enough evidence to prescribe statins for the brain.\nBut today's study looked at people before any hint of dementia.\nThose who were taking a cholesterol-lowering statin such as Lipitor, had a surprising result.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The reporter talks to one of the researchers on the study, and an expert with no relationship to the study. \nThis is adequate sourcing. A third source would have improved the story.\u00a0 ", "answer": 1}, {"article": "Cytology-based screening, known as the Pap test or Pap smear, is used to detect abnormal cells.\nHowever, reports of rare HPV-negative, Pap-test-positive cancers are motivating continued use of both tests (cotesting) despite increased testing costs.\nResearchers were searching for realistic performance data to quantify the additional benefit of the Pap test component of cotesting, as the costs of intensive screening of all women using two screening tests are substantial.\nA new paper in the Journal of the National Cancer Institute finds that testing for cervical cancer using HPV testing in addition to the Pap smear is unlikely to detect cancer cases that wouldn't be found using HPV testing alone.\nThe main goal of cervical screening programs is to detect and treat precancer before cancer develops.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The funder (NIH/National Cancer Institute) is listed on a sidebar of EurekAlert! where the release is hosted. We encourage releases to also include funders in the release itself. There do not appear to be any conflicts.", "answer": 1}, {"article": "ADVERSE EVENTS \n\nNasal pain, discomfort or burning (10.3%); transient electrical discomfort (5.2%); nosebleed (5.2%); nasal congestion (3.1%); headaches (2.1%); trace blood, dot heme in nostril (2.1%); facial pain (2.1%); sore eye (1.0%); sinus pain (1.0%); periorbital pain (1.0%); runny nose (1.0%); nasal ulcers (1.0%); and light-headedness (1.0%).\nThe new advancement is an addition to Allergan's current eye care portfolio.\nAllergan is focused on developing, manufacturing and commercializing branded pharmaceuticals, devices and biologic products for patients around the world.\nThere have been two clinical studies showing positive safety and effectiveness of the device in the increase of tear production completed with 145 aqueous deficient dry eye adult patients.\nStudy 2 is a prospective, single-arm, multicenter, open-label clinical trial in which participants used TrueTear\u2122 to stimulate tear production for 180 days.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "Although readers will assume that Allergan (and Oculeve, which first developed the device before it was bought by Allergan) funded the studies, the release includes a quote from a university professor without disclosing that he serves as an advisor or consultant to Allergan and makes paid speeches on behalf of the company. (See \u201cFaculty and Disclosures\u201d link in this Medscape CME article.)", "answer": 0}, {"article": "Hot flashes typically begin in the year or so before menopause and tend to abate in the years afterward.\nTo prove it is effective in reducing hot flashes, the Mayo team needed to demonstrate that it was superior to sham, or placebo, treatment.\nExperts in women's health say they are one of the most common ailments for which women use alternative medicine and that interest in non-hormonal treatments has increased as a result of the WHI findings.\nThe 2,000-year-old treatment is widely used around the world, according to the National Center for Complementary and Alternative Medicine (NCCAM), part of the National Institutes of Health (NIH).\nVincent's group recruited 103 women between the ages of 45 and 59 who reported that they had at least five hot flashes per day and were not using any other treatments for them.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Article cites an author of the study, another expert, and a National Institutes of Health consensus document. ", "answer": 1}, {"article": "Anderson.\nThe benefits were greater in women aged 45 to 49, vs. those aged 40 to 44, the researchers said.\nTo further stir the pot, a Norwegian study released last week found that routine mammograms accounted for only about one-third of the decline in breast cancer death rates seen recently.\nThe study, done in Sweden, found that women who were screened cut their risk by 29 percent.\nWEDNESDAY, Sept. 29, 2010 (HealthDay News) -- Another study evaluating the value of mammograms for younger women finds that screening can lower the risk of dying from breast cancer for women in their 40s.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story cites independent sources, including the Swedish study author and chair of the American Society of Clinical Oncology\u2019s communications committee, as well as other breast cancer researchers who found a benefit in screening younger women and a decline in breast cancer mortality.\u00a0 However, these sources do not\u00a0 discuss the downsides of treatment. No one is cited to discuss the downsides of mass screening in a group where the risks may outweigh the benefits.\u00a0 Risks of screening low to average risk women in their early 40s include: overtreatment, false positive biopsies, anxiety, and in some cases, a fear and avoidance of future screening when mammography may be of greater benefit. Why not interview a member of the USPSTF to discuss their reaction to this recently published data? The USPSTF guidelines also do note that women at low-average risk discuss screening with their doctor. There is no mandate that women 40-49 not have access to annual screening. \nQuotes from both Dr. Jennifer Obel of ASCO and from study co-author Hakan Jonsson apparently came from an ASCO teleconference.\u00a0 There was no evidence of any independent research to find independent experts to comment on the study. \n", "answer": 0}, {"article": "By the time most lung cancers are diagnosed -- which usually involves an invasive examination of the lungs -- patients already have advanced malignancies.\nMaybe one day, screening could be done using an even simpler nasal or sputum test, the researchers said.\nCurrently, there is no good way to detect lung cancer -- the number one cancer killer -- in its early stages when it's most treatable.\nThe minimally invasive procedure involves using a small brush to collect a smattering of cells from the windpipe (a bronchoscopy), explained study co-author Andrea Bild, an assistant professor of pharmacology and toxicology at the University of Utah in Salt Lake City.\nThe study findings were published in the April 7 issue of the journal Science Translational Medicine.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Barely satisfactory.\u00a0 One independent expert quoted \u2013 but one whose quote offered no analysis.\u00a0 Financial interest of the lead investigator is mentioned.\u00a0 ", "answer": 1}, {"article": "The U.S. Food and Drug Administration said Tuesday it has approved Cotellic, a drug produced by Swiss biotech company Roche, for use in combination with the vemurafenib medication as a treatment for advanced melanoma.\n\nThe drugs are intended to target the illness after it has spread to other parts of the body or can\u2019t be removed by surgery.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "There appear to be no outside sources used in this story.\u00a0 All the information comes from the FDA. However, because of that, there is no conflict of interest as the drug manufacturer/distributor is identified, but no information apparently comes from them.\nIt is important to remember here that the role of the FDA is to approve based on effectiveness and safety and the bar for both in a disease like melanoma is low. How clinically useful this drug will prove to be is open to question and it would have been nice to hear from some independent oncologists about that.", "answer": 0}, {"article": "This benefit is thought to come from the omega-3 fatty acids in fish, although studies of fish oil supplements have produced disappointing results in people who already have Alzheimer's.\nIn a new study, imaging scans showed that regular fish-eaters were less likely to have brain cells die off in the area of the brain responsible for short-term memory -- recalling a phone number that was just heard, for example.\nSeveral studies have linked a diet rich in certain fish to a reduced risk of Alzheimer's disease.\nNov. 30, 2011 (Chicago) -- Older people who eat baked or broiled fish at least once a week may be boosting their brain health.\n\"The new study is the first to establish a direct relationship between fish consumption, brain structure, and Alzheimer's risk,\" Raji says.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story turned to the chief medical and scientific officer of the Alzheimer\u2019s Association for comment.\u00a0 But the quote used from him didn\u2019t contribute much to an evaluation of the study.\n ", "answer": 1}, {"article": "This signal is passed to a computer that decodes it, and the resulting instruction is then sent to a sleeve he wears on his forearm that stimulates the muscles that move his wrist and fingers.\nThat's why the device requires training every time Burkhart uses it.\nFor starters, the device that records the brain signals will need to be much smaller so it's fully implanted under the paralysed person's skin.\nDetails of the system that allows him to do this, developed by scientists at Ohio State University and Battelle Memorial Institute, are published in the journal Nature today.\n\"So the machine and the person are learning together, and after that 10\u201315-minute period there's a dramatic improvement, it's been really amazing to watch.\"\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story includes strong context and cautionary statements from two independent sources. However, we cannot give it a Satisfactory rating because it doesn\u2019t tell readers that the researchers have an interest in patents for the hardware and software they are developing. These financial interests were clearly noted in the Nature journal article and should have been included in the story.", "answer": 0}, {"article": "\"It's only been relatively recently that energy surplus has become a problem,\" Wu said.\nThe research was supported by the Human Frontier Science Program, Edward Mallinckrodt Jr. Foundation, National Institutes of Health and American Heart Association.\nAnd because it is already used widely in the food industry, it might be easier to convince patients to stick to a cinnamon-based treatment than to a traditional drug regimen.\nResearchers in the lab of Jun Wu, research assistant professor at the LSI, wanted to better understand cinnamaldehyde's action and determine whether it might be protective in humans, too.\nBut the mechanisms underlying the effect were not well understood.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The funding sources are clearly included in the news release. There are no conflicts of interest listed in the news release or study.", "answer": 1}, {"article": "If a robot is to be enlisted, he recommends asking how the procedure would be performed if the robot is not available or if it doesn\u2019t work.\nThe robotic equipment provides better three-dimensional vision, increased range of motion and intuitive, downscaled movements, while adding a few thousand more dollars to the procedure\u2019s price tag, the authors note.\nThe researchers found that the two advanced minimally invasive techniques led to similar results, and both appeared to be generally superior to the traditional open procedure.\n\u201cRobotics increases the chance that a hysterectomy can be done by laparoscopy,\u201d he added.\n\u201cRobotics makes it easier for surgeons to transition from open to minimally invasive procedures,\u201d he added.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quoted two physicians who were not involved in the study.", "answer": 1}, {"article": "Professor Paul Workman, Chief Executive of The Institute of Cancer Research, London, said:\n\n\"Nivolumab is one of a new wave of immunotherapies that are beginning to have an impact across cancer treatment.\nThe trial was led in the UK by Professor Kevin Harrington of The Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust, and involved 20 research organisations from around the world.\nThis trial found that it can greatly extend life among a group of patients who have no existing treatment options, without worsening quality of life.\nSome of the data was presented at 16:25 CEST today (Sunday) at the European Society for Medical Oncology 2016 Congress in Copenhagen.\nNivolumab became the first treatment to extend survival in a phase III clinical trial for patients with head and neck cancer in whom chemotherapy had failed - and it did so with fewer side-effects than existing therapeutic options.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release makes clear that the study was funded by Bristol Myers Squibb. That\u2019s good. The release does not, however, tell readers that some of the study authors received personal fees from Bristol Myers Squibb, in addition to the grant funding. That information can be found in conflict-of-interest disclosure documents on NEJM\u2018s site.", "answer": 0}, {"article": "In Canada, heart failure patients stay an average of almost 10 days for each hospital admission, accounting for 1.4 million hospital stays a year.\nSince it opened in 1997, the Centre has saved and improved the lives of cardiac and vascular patients from around the world.\nThe first Canadian patient implanted with the heart monitor will be among 25 patients within the Ted Rogers Centre for Heart Research at the Peter Munk Cardiac Centre to be fitted with the device over the next nine months.\nThe CardioMEMS\u2122 HF System is designed to monitor heart failure patients whose condition is serious but who are not so ill that the technology cannot improve their outcome.\nThis is a big game-changer.\u201d\n\nFunded by the Ted Rogers Centre for Heart Research, the device called CardioMEMS\u2122 HF System was successfully implanted by interventional cardiologists at the Peter Munk Cardiac Centre in March 2017.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "We found no conflicts of interest associated with this news release. The release discloses the fact that the CardioMEMS implantation procedure was funded by the Ted Rogers Centre for Heart Research.\nWe give the news release a Satisfactory rating here.", "answer": 1}, {"article": "Excessive drinking alone is linked to 88,000 deaths each year.\nThe good news is that the research suggests the spiritual aspect doesn\u2019t fully explain why the 12 steps are effective for some people.\nAnd since it\u2019s only one study, it\u2019s possible that the results were biased in some other way.\nWhile alternatives like SMART or LifeRing do exist, they\u2019re not nearly as available as AA \u2014 and they certainly aren\u2019t built into professional treatment programs in the same way as the 12 steps.\nThat\u2019s long led researchers to suspect that alternative mutual help groups could work.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes an expert source who was not affiliated with the research and who provides useful context about key limitations of this study. It doesn\u2019t appear that there are any undisclosed conflicts of interest.", "answer": 1}, {"article": "Invented 16 years ago by a radiologist who got the idea while playing video games on a flight simulator during advanced training at Johns Hopkins, virtual colonoscopy has become an increasingly popular alternative to standard, or optical, colonoscopy, which is typically performed by a gastroenterologist.\nInitially regarded as a high-tech novelty, the new procedure has in recent months received key endorsements as a first-line screening test from influential medical groups, notably the American Cancer Society, after several large studies found it to be effective at finding large polyps.\nMedicare's decision has sparked a furious lobbying campaign.\n\"It sounded good to me,\" said Rowe, pleased that he could schedule the $800 procedure for 7:45 a.m. at a downtown medical building.\nCurrently about half of Americans over 50 are screened for the disease; some shun traditional colonoscopy, which is the only way to remove polyps, because of its invasive nature.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes multiple sources with differing persepctives.", "answer": 1}, {"article": "\u201cIf out of 10 years the patients have left to live we can keep them at home in a relatively mild state of the disease for three, four, five years, it\u2019s a lot.\u201d\n\nAccording to Alvaro Pascual-Leone, director of the hospital\u2019s Berenson-Allen Centre for Non-invasive Brain Stimulation, brain stimulation - or transcranial magnetic stimulation - involves a very low current applied to a specific part of the brain and is approved by the FDA for treatment of a variety of ailments and diagnostic applications.\nNeuronix received European approval several months ago and has installations in the UK and Germany.\nThe device, which combines electromagnetic stimulation with computer-based cognitive training, is already approved for use in Europe, Israel and several Asian countries such as Singapore.\nThe study\u2019s results will be submitted for publication in the coming weeks and a follow-up study on 30 patients is planned.\nPascual-Leone, who is principal investigator in the Harvard trial, said that of 12 patients in the study, six received the real treatment and all showed cognitive improvement.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story only quoted the company CEO and Dr. Alvaro Pascual-Leone.\u00a0 But it didn\u2019t disclose that Pascual-Leone is on the company\u2019s scientific advisory board.\nThere was no truly independent perspective in the story.", "answer": 0}, {"article": "\"This is outside the box. I've never used it this far out,\" Metz said. \"My radar is up if I see [such an injury] again. As we get more follow-up from David, it will be important to publish this case so people will be aware.\"", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Besides the one reference to Kaiser Health News, all the sources had connections to the patient.", "answer": 0}, {"article": "BioZorb has received 510(k) clearance from the U.S. Food and Drug Administration.\nThe study also noted that the device provides a helpful guide for post-treatment mammograms and other long-term follow-up to check for any cancer recurrence in these patients.\nThe article reports that the device provides clear visualization of the surgical site where the tumor was removed, thereby improving communication between the surgeon and radiation oncologist.\nBy providing better targeting, they said, the marker could also play a role in facilitating the use of external beam partial breast irradiation.\nThe authors said use of the marker facilitated their shift toward these shorter courses of radiotherapy.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The news is provided by Focal Therapeutics, maker of the implant. \u00a0There is no mention in the news release of any potential conflict of interest, but the published study noted one of the authors had a financial arrangement with Focal.", "answer": 0}, {"article": "Fluctuating levels of levodopa result in erratic periods of muscular control and involuntary movements throughout the day, disrupting activity at least half a dozen times a day.\nThe long-acting therapy is taken once-daily at bedtime.\nThese patients have little recourse, other than opting for deep brain stimulation, a surgical procedure that involves blocking electrical signals from targeted areas in the brain.\nAdamas is also testing the drug to treat walking impairment in patients with multiple sclerosis.\nAn estimated 90 percent of levodopa-treated patients, about 200,000 people in the United States, suffer from LID, the company said.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Outside sources not connected to the study would have been a great addition to the story, but there were none.", "answer": 0}, {"article": "\"You've got to have a teacher right there in front of you teaching according to experience,\" he said.\nAn outside expert, however, said the study is too limited in size and scope to allow conclusions as to whether meditation really reduces risk of death or disease.\nEven though the findings in this study were statistically significant, the new study was too small to be conclusive, Fonarow said.\nBut a cardiology expert said that although the study adds to evidence supporting meditation, it doesn't prove a cause-and-effect relationship between the practice and better health outcomes.\nThe new study focused on Transcendental Meditation.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "An independent cardiologist is extensively quoted, bringing an appropriate dose of skepticism to the\u00a0coverage.", "answer": 1}, {"article": "However, prostate cancer is one of the few cancers that\u2019s not strongly linked to smoking (and falling cigarette consumption over the past 40 years is a major reason for falling cancer rates).\nIt\u2019s saying that, for most men, the (albeit small) risk of sexual dysfunction and urinary leakage from eventual treatment is not worth it, given the even smaller chance that PSA testing could save your life.\nAnd, as the debate over PSA testing shows us, early diagnosis is only useful if early treatment can help patients live longer and healthier lives, preventing progression to advanced-stage cancer down the line, but without increasing the risks of other health problems too much in the process.\nMany health experts think that\u2019s too much risky treatment to justify the results.\nNow, a new study looks at government data and finds that, without PSA testing, the U.S. would have three times as many patients each year diagnosed with advanced-stage prostate cancer \u2014 and the vast majority of those cases would be fatal.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "It is clear that the writer brings a lot of reporting depth to the story and has a clear understanding of the topic. An independent voice or two might have helped the story show readers where the preponderance of the evidence now lies instead of making it look as if this is merely a debate between \u201cbetween public health experts who have largely turned away from PSA screening, and many practicing clinicians who feel the test has helped their patients immensely.\u201d That is a simplistic dichotomy and the story never really answers the question it poses of \u201cWhy Can\u2019t Doctors Agree?\u201d", "answer": 0}, {"article": "A widely anticipated study suggests that hormone therapy started soon after menopause can ease depression, anxiety, hot flashes and other adverse symptoms that many women face, without increasing risks for cardiovascular disease.\n\nThere was no increase in breast cancer, stroke, heart attack or blood clots, but the study's researchers said the sample size was too small and the study time too short to draw firm conclusions.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "No independent sources are cited in the story. Direct citations come from two sources \u2013 both of whom are researchers involved in the study. The story does bring up the fact that KEEPS was funded by the Kronos Longevity Research Institute, a nonprofit organization in Phoenix. No conflicts of interests are listed. But it\u2019s not clear who actually paid for this substantial study. A non-profit institute does not mean that it is free of pharmaceutical industry support.\u00a0The organization Kronos institiute is supported by the nonprofit \u201cAurora Foundation\u201d, which gave $34 million for this study according to Indiana University Philanthropy website. Who are they?", "answer": 0}, {"article": "The 87.9% rate of laryngeal preservation at 2 years for CRT found in this trial is similar to the rate reported for the use of radiotherapy and concomitant cisplatin in Radiation Therapy Oncology Group 91-11 trial (n = 547).13\n\nPatients who undergo a laryngectomy often experience a difficult adjustment process.\nPatients began treatment within 2 weeks after this initial evaluation, as determined by the randomization procedure.22 Patients who underwent no surgery or less extensive operations were censored at death or date of last contact.\nA pharmacologic profile was also performed weekly on patients receiving cetuximab infusion (CRT group).\nOne of the largest randomized clinical trials was designed to evaluate laryngeal preservation compared with radiotherapy alone, concomitant chemoradiotherapy, and induction chemotherapy followed by radiotherapy.13,14 Each treatment group included at least 180 patients, thus providing much greater statistical power than the current communication.\nThe median durations of treatment were 52, 46, and 43 days for once daily, twice daily, or concomitant boost, respectively, for patients treated with CRT and 52, 44, and 43 days, respectively, for patients treated with radiotherapy alone.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release tells readers that the work was funded by Eli Lilly and Company, but refers readers to the journal article for information about financial disclosures, potential conflicts of interest, etc. This is not okay, for two reasons. First, while the release mentions Eli Lilly\u2019s funding, it doesn\u2019t make clear Lilly\u2019s financial ties to cetuximab. Lilly manufactures cetuximab and receives royalties on Erbitux worldwide (though it is marketed by different companies, depending on where it is being sold). In short, Lilly has a vested interest in seeing an increase in cetuximab use (the drug reportedly brought in $723 million in 2014 \u2014 in North America alone). Second, many readers, possibly most readers, may not have access to the journal article. And if an institution knows that information is worth mentioning to readers (such as whether researchers had conflicts of interest), then an institution should not make readers put in extra legwork to find that information. And there is certainly relevant information to share here. The lead author reported working as a consultant for Lilly. Two co-authors are Lilly employees. A third co-author is a former Lilly employee and owns Lilly stock. And a fourth co-author works for Merck KGaA, which markets cetuximab outside of North America. In other words, five of the nine authors have clear conflicts of interest that are not disclosed in the release.", "answer": 0}, {"article": "\u201cHe said, \u2018I don\u2019t want to spend my time doing this,\u2019 \u201d recalled his son, Dr. Gerald A. Hladik.\nHe wanted to be able to go to the beach.\u201d\n\nA nephrologist at the University of North Carolina School of Medicine, Dr. Hladik understood better than most how kidney dialysis could consume a patient\u2019s days.\nGerald J. Hladik was 74 when the day long anticipated by his doctors arrived: His kidneys, damaged years earlier by a viral infection, had lost 85 percent of their function.\nAn IBM retiree, he loved fishing, boating and gardening \u2014 and hated hospitals.\nSo after considerable discussion, Mr. Hladik decided to skip the three weekly trips to a renal center, along with the resulting fatigue and dietary and travel restrictions.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "There are numerous sources both quoted and cited in the story, so we are giving it a pass here. At the same time, we would have liked to have heard the evidence-based opinion of a strong advocate for end-of-life dialysis. The counterpoint in this case might have been a doctor saying that patients have a hard time sharing in decisions or sometimes do not want to do so.", "answer": 1}, {"article": "That's the tantalizing premise behind Deplin, a prescription form of the B-vitamin folate. Although it has been on the market since 2006, Deplin is generating growing buzz at psychiatric conferences and among clinicians and patients, particularly those who haven't responded to antidepressants or did for a while only to have their depression return.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Barely satisfactory. The story included comments from a number of sources, including a company-supported investigator, a representative of a mental health advocacy group, and non-affiliated clinicians. It also did a good job of disclosing relationships with Deplin maker Pamlab where necessary. What we wanted to see more of were comments specifically about the studies\u00a0supporting Deplin as a depression treatment. Most of the sources talk only about their clinical experience with the\u00a0supplement or the general concept of using it.\u00a0We\u2019d like to see a higher priority placed on analysis of the evidence\u00a0that Deplin\u00a0works. ", "answer": 1}, {"article": "Anderson Cancer Center in Houston.\nThis targeted form of treatment takes advantage of a weakness in the BRCA gene to further cripple the cancer cell's ability to repair itself, grow and spread, said Weiss, who was not involved with the study.\nSimilar drugs have already been used to treat advanced, BRCA-mutated ovarian cancer, according to the agency.\nThe trial was funded by drug maker Pfizer, and the results were published Aug. 15 in the New England Journal of Medicine.\nIn January, the FDA approved the first PARP inhibitor, Lynparza, to treat BRCA-mutated breast cancer.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story mentions the study was funded by the drugmaker, Pfizer. It also clearly identifies one source, Jennifer Litton, as the lead researcher on the story.\nThe other quoted source, Marisa Weiss was not involved in the research. However, both Weiss and the organization she works for, Breastcancer.org, have received money from Pfizer. This was not disclosed in the story.", "answer": 0}, {"article": "\"It may be that it helps with relaxation of muscles that are tense,\" Deyo says.\nPeggy O'Brien-Murphy was among the study participants.\nNo one knows exactly how massage works to relieve pain, says Dr. Richard Deyo of Oregon Health Sciences University, who also took part in the study.\nFor an active person, this was devastating.\nThe third group got the usual care \u2014 medication and physical therapy.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "No truly independent source was interviewed \u2013 only two researchers involved in the study.", "answer": 0}, {"article": "The requested URL /usnews/health/articles/070520/28healthwatch.lede.htm was not found on this server.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The only source quoted in this story was the senior author of the paper reported on.\u00a0 It would have been helpful to have an independent source comment on the results presented.", "answer": 0}, {"article": "In deep brain stimulation, surgeons insert wires into the brain that allows a specific region to be continuously hit with an electronic pulse.\nDr. Samuel James Collier, an assistant professor of psychiatry at the University of Texas Southwestern Medical Center at Austin, predicted that even if deep brain stimulation turns out to be an effective treatment for depression, it'll be far from the first line of defense.\nDeep brain stimulation has been around for more than 20 years, Mayberg said, and is commonly used to treat Parkinson's disease.\nPrevious research by Mayberg and others suggested that deep brain stimulation had potential as a treatment for depression.\nAnd for now, the research is preliminary, so it's too early to know for sure if the treatment is appropriate to be used for any kind of depression.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story says that the St. Jude Medical Neuromodulation company \u201cprovided consulting fees to Mayberg and some of the other study authors\u201d and \u201cis currently recruiting patients for a study that could pave the way for its approval as a treatment for depression.\u201d The story also quotes\u00a0Samuel James Collier, M.D., assistant professor of psychiatry, University of Texas Southwestern Medical Center at Austin, who provides a welcome dose of skepticism to the story, saying \u201cMedications and ECT \u2014 electroconvulsive therapy \u2014 are clearly safer, better tolerated, and do not embody a large surgical risk. \u2026I can\u2019t think of a scenario where deep brain stimulation would be considered even remotely before medications and ECT were exhausted.\u201d\n\u00a0", "answer": 1}, {"article": "The potential use of psilocybin in patients diagnosed with life-threatening diseases comes at a moment when medical care at the end of life is a subject of growing concern among patients and physicians. Research finds it's still common for dying patients to get painful and futile procedures. Palliative and hospice care, both aimed at easing the discomfort of the seriously ill, are growing specialties in American hospitals. An increasing number of patients, meanwhile, are demanding the right to die with a physician's help.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story clearly states who funded the studies, and what that organization\u2019s long-term goals are. Further, the story clearly identified individuals quoted in the story who have ties to the studies or the funding organization. Lastly, the story incorporates input from an independent expert.\nHowever, the story would have been stronger if there had been a skeptical take on the research, which saw\u00a0in some other coverage, such as this New York Times piece.", "answer": 1}, {"article": "Newly postmenopausal women who received estrogen via a skin patch had reduced beta-amyloid deposits, the sticky plaques found in the brains of people with Alzheimer\u2019s disease, a Mayo Clinic study published this month in the Journal of Alzheimer\u2019s Disease found.\nThe researchers used positron emission tomography, also known as a PET scan, to look for the brain amyloid deposits three years after the trial ended.\n\u201cThis study showed, for the first time, that the brain amyloid deposition \u2500 a hallmark of Alzheimer\u2019s disease \u2500 is reduced in newly postmenopausal women who received 17beta-Estradiol patch form of hormone therapy,\u201d says lead author Kejal Kantarci, M.D., a Mayo Clinic radiologist.\nThe oral treatment was not associated with lower amyloid deposition.\n\u201cIt also may have a significant impact on women making the decision to use hormone therapy in the early postmenopausal years.\u201d\n\nStudy co-authors are Val Lowe, M.D.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "Funders are identified, and\u00a0the single scientist\u00a0in the release\u00a0is clearly identified as the study\u2019s lead author.", "answer": 1}, {"article": "Tai chi is a mind-body exercise that originated as a martial art in China, utilizing slow, gentle movements to build strength and flexibility, as well as deep breathing and relaxation, to move qi, or vital energy, throughout the body.\n\"This could represent an ideal exercise for fibromyalgia sufferers.\nWhile larger studies are needed to confirm the findings, tai chi looks promising as an alternative treatment, Yeh said.\n\"But in my opinion, the most important part is mental.\nDoctors will often suggest exercise, sleep hygiene techniques and medications to treat the condition, but often with limited success, said Dr. Gloria Yeh, an assistant professor of medicine at Harvard Medical School, who wrote an accompanying editorial in the journal.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story does cite the opinions of a researcher who wrote an accompanying article in the journal. More outside voices would have been a nice addition. This criterion is barely satisfactory. ", "answer": 1}, {"article": "\"For black tea lovers, there may be a new reason to keep drinking it,\" she said.\nThe new findings show that black tea polyphenols, which are too large to be absorbed in the small intestine, stimulate the growth of gut bacterium and the formation of short-chain fatty acids, a type of bacterial metabolites that has been shown to alter the energy metabolism in the liver.\nDr. Zhaoping Li, director of the UCLA Center for Human Nutrition, chief of the UCLA Division of Clinical Nutrition and the study's senior author, said the findings suggest that the health benefits of both green tea and black tea go beyond their antioxidant benefits, and that both teas have a strong impact on the gut microbiome.\nThe new study also concluded that both green tea and black tea have different effects on liver metabolism.\nThe findings build on a 2015 UCLA study that demonstrated that both green tea and black tea helped prevent obesity in mice that consumed a high-fat, high-sugar diet.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The funders of the study are disclosed and there don\u2019t appear to be any obvious conflicts of interest.", "answer": 1}, {"article": "\"But in an emergency room, while there are challenges as well, bedside blood tests are much more readily drawn and quickly analyzed so you can often get the results in minutes.\nThe investigators stressed that their evaluation is based on a small group of participating patients, and that more extensive research will have to be done to confirm their initial success.\nDr. Gregg Fonarow, a professor of cardiology at the University of California, Los Angeles, said that if further research were able to establish its effectiveness, a breath-driven tool for identifying heart failure would be a helpful diagnostic innovation -- but more so in a doctor's office or clinic than in the hospital.\nThe findings were published March 25 in the Journal of the American College of Cardiology.\nThe study authors pointed out that the most common reason American patients are admitted to a hospital is when there is a suspicion of heart failure -- a tough-to-treat condition in which the heart's pumping action grows gradually weaker over time.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "There are quotes from an independent expert. The journal that published the research reported that it was funded by state and federal grants, and that the researchers did not report any disclosures relevant to this study.", "answer": 1}, {"article": "The scans, called coronary computed tomography angiography or CCTA, produce a detailed image of the heart that reveals cholesterol buildups in the coronary arteries.\nYet there\u2019s no evidence that treating people based on heart scan results does any good, said Dr. John McEvoy, of Johns Hopkins Ciccarone Center for the Prevention of Heart Disease in Baltimore, who led the new study.\nIn an editorial, Dr. Michael S. Lauer of National Heart, Lung, and Blood Institute in Bethesda, Maryland, said the new study serves as a reminder of the downsides of screening.\n\u201cTesting might lead to more harm than good,\u201d McEvoy told Reuters Health, adding that heart scans may cost $600 or more.\nAccording to McEvoy, doctors should focus on patients\u2019 lifestyle and traditional risk factors such as smoking and obesity.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "An author of the paper, and the author of an accompanying editorial were quoted.", "answer": 1}, {"article": "Professor Paul Workman, Chief Executive of The Institute of Cancer Research, London, said:\n\n\"If we're going to drive further improvements in survival from cancer, it's essential that we find ways of prolonging life in people whose cancers have evolved and become resistant to treatment.\nThe new research, published today (Thursday) in The Lancet Oncology, shows that even women with specific genetic changes conveying resistance to hormone therapy can benefit from the new drug combination.\nWe hope our results lead to the adoption of this drug combination in breast cancer, where it delays the need to start chemotherapy by an average of nine months.\nThis trial is an exciting example of one of the most promising approaches to overcoming drug resistance, by combining drugs with different mechanisms of action to block off cancer's escape routes.\nThe international study, led in the UK by Dr Nicholas Turner, from The Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust, updates the results of a major phase III trial published last year.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release clearly states that Pfizer funded the study. Pfizer produces palbociclib, one of the drugs studied in the trial.", "answer": 1}, {"article": "One recent study, for example, found that pregnant women who started taking selective serotonin reuptake inhibitors (SSRIs) in the second or third trimester had a higher risk of preterm delivery than other women.\nIt is unclear, Manber said, why acupuncture might help lessen the severity of depression.\nThe study, which followed 150 pregnant women with major depression, tested \u201cdepression-specific\u201d acupuncture against massage and acupuncture sessions that, according to traditional Chinese medicine, does not specifically target depression.\nAll completed a standard measure of depression severity at the outset and again after four and eight weeks of treatment.\nOverall, 63 percent responded to the therapy, versus 37 percent of the \u201ccontrol\u201d acupuncture group and half of the massage group, according to findings published in the medical journal Obstetrics & Gynecology.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "No independent experts were quoted in this story.\u00a0\u00a0 ", "answer": 0}, {"article": "\"It's very stressful because you're sleep-deprived, you're not eating right ... you're working back-to-back shifts and you're trying to catch up on sleep but you can't,\" Dalechek said.\nThe online program included sessions about how to put feelings of stress or despair into perspective.\nGuille said offering web-based therapy routinely to medical residents could be beneficial, if her research results are confirmed in a broader study.\nThe research involved about 200 medical interns \u2014 residents in their first post-graduate year, which is often one of the most intense periods of doctor training.\nThe study involved interns at Yale University and the University of Southern California.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story provides comments from a psychiatry resident not affiliated with the study who offers an important view from the inside.With that being said, we wish the story had included the views of an expert in the field, commenting specifically on the intervention that\u2019s the basis for the story.", "answer": 1}, {"article": "\"This is the holy grail,\" says Suresh S. Ramalingam, MD, associate professor and director of the lung program at Emory University's Winship Cancer Institute in Atlanta.\nBut that test has caused controversy because it falsely detects cancer in about one out of four people, leading to further invasive procedures.\n\"The whole field is focused on using something that's readily available that does not involve an expensive surgery or scan that would allow us to find early cancers,\" says Ramalingam, who is developing technology that aims to replicate the ability of dogs to smell trace amount of chemicals produced by cancerous tumors.\nAug. 17, 2011 -- German researchers say that highly trained dogs are able to reliably sniff out lung cancer in human breath.\nHe was not involved in the research.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes independent sources and identifies that one expert, who is not tied to the European research, is also working in a related area \u2013 developing technology to mimic the canine sniff test.", "answer": 1}, {"article": "They are packed full of growth factors, of healing factors, and when given into a specific area, you get a hyper-healing response,\" Gearhart says.\nHe is one of the few patients to get it so far \u2014 clinical trials are now testing PRP's safety and effectiveness.\nBornstein was thrilled to get back on the field quickly.\nBut Dr. Michael Gearhart did.\nSide effects reportedly have been minor; it seems like the biggest problem so far: The needles hurt.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Only one physician and only one patient\u2019s experience were highlighted.\u00a0 This story was crying out for some independent perspective. ", "answer": 0}, {"article": "That view is shared by Deborah Giaschi, a professor of ophthalmology and visual sciences at the University of British Columbia in Vancouver who has conducted MRI studies of the brains of people with dyslexia. \"There's really no scientific basis\" for ChromaGen lenses, she says. In her opinion, the claim that the lenses slow down visual processing doesn't make sense. Even if the lenses had that effect, she doesn't see how that would help anyone read.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story didn\u2019t settle for the manufacturers\u2019 claims.\u00a0 It turned to four other sources.", "answer": 1}, {"article": "Acupuncture designed to treat depression appears to improve symptoms in pregnant women, suggesting it as an alternative to antidepressant medication during pregnancy, a study found.\n\nThe study, published Monday in the journal Obstetrics & Gynecology, is the largest to date examining the effectiveness of acupuncture to treat depression in pregnant women. It was funded by a grant from the government's Agency for Healthcare Research and Quality. \"Acupuncture that we have tested works for pregnant, depressed women,\"...", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes only the lead author on the study. The story should have quoted additional, independent experts who could have provided much needed perspective on the importance of \u2013 or limitations of \u2013 these new findings.", "answer": 0}, {"article": "Among those 40 to 49 who had regular screening, for every 1,000 women tested, 121.2 had a false positive.\nFor every 10,000 women screened repeatedly over 10 years, four lives are saved in women 40 to 49; eight in women 50 to 59; 21 in women 60 to 69; and 13 in women 70 to 74, the task force found.\nThe task force said it concluded \u201cwith moderate certainty\u201d that the benefit was moderate in women 50 to 74 and small in women 40 to 49.\n\u201cThe science supports mammography as an important tool in the fight against breast cancer,\u201d said Dr. Michael LeFevre, a former chairman of the task force and a professor of medicine at the University of Missouri.\nThe guidelines relied in part on a study of records from 405,191 women who had digital mammograms from 2003 to 2011, which found that false positives were common, especially in younger women.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story did a good job of incorporating input from multiple independent sources.", "answer": 1}, {"article": "The California Walnut Commission offices are located at 101 Parkshore Dr., Ste.\nThis study was supported in part by funds from The International Tree Nut Council Nutrition Research and Education Foundation.\nOf 1,301 articles surveyed, 61 trials met eligibility criteria for this systematic review and meta-analysis, totaling 2,582 unique participants.\nWalnuts were investigated in 21 of the 61 trials, more than any other nut reviewed in this study.\nAdditionally, results showed that tree nut consumption may be particularly important for lowering the risk of heart disease in individuals with type 2 diabetes.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release clearly states that the study is sponsored and funded by the California Walnut Commission with additional funding from the International Tree Nut Council Nutrition Research and Education Foundation.", "answer": 1}, {"article": "Older people tend to get less slow-wave sleep and are at greater risk for memory impairment.\nBut first, says Zee, larger and longer studies are needed to confirm the findings and show that there are benefits to long-term use, rather than on just one night.\nThe researchers hope to develop an affordable device that people can use at home.\nMusic, nature sounds and white (or pink) noise apps may still help improve sleep, she says\u2014which, in itself, is good for the body and for the brain.\n\u201cIt\u2019s just noticeable enough that the brain realizes it\u2019s there, but not enough to disturb sleep.\u201d The sounds were timed to match their slow-wave oscillations.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The only source quoted in the article is a\u00a0study author. The article states that one of the study authors (it\u2019s not clear whether it\u2019s the one quoted or not) has co-founded a company to develop a commercial device.\nWe applaud the story for including this conflict of interest but we\u2019d like to see at least one source not involved in the study for an unbiased perspective.", "answer": 0}, {"article": "Related: New Test Detects Heart Disease Risk, Especially for Black Women\n\nIt\u2019s not just the fat cells that lead to heart disease, the No.\nRelated: Why Young Women are Having Heart Attacks\n\nThe team studied more than 450 people having heart bypass surgery, removing some of the fat clogging their arteries.\n\u201cTreatments that are known to reduce the risk of heart attacks, such as statin drugs, reduce inflammation much more than any detectable reduction in coronary artery narrowing,\u201d said Oxford\u2019s Keith Channon, who also worked on the study.\nResearchers say they\u2019ve developed a better way of scanning someone\u2019s heart to predict who is most at risk of a heart attack or stroke \u2014 long before conventional imaging methods can do it.\n\u201cWe are now further validating our method in larger numbers of patients in large prospective clinical studies to document and confirm the predictive value of this method for future heart attacks,\u201d Antoniades said.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The article appears to quote only those who conducted the study.", "answer": 0}, {"article": "\"We compare the colored glasses to being like a brace or cast but for the brain,\" he says.\nWe believe the use of the colored glasses that provide photophobia mitigation has added benefits superior to dark sunglasses, especially for indoor lighting.\"\nPhotophobia is so common that many neurosurgical intensive care units consider it standard operating procedure to keep lights dimmed in rooms containing TBI patients says Clark.\nThe goal is to help the concussion patient feel better as the brain heals.\nAdditional researchers on the study include Jon Divine, MD, a professor in the Department of Orthopaedic Surgery at the UC College of Medicine and head team physician for University of Cincinnati Athletics.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release states, \u201cThere was no funding used for this study.\u201d", "answer": 1}, {"article": "Dr. Scolnick has not seen the results of the Novartis trial, but was told of them and concluded that if the drugs work in fragile X, \u201cthere\u2019s nothing to say that they won\u2019t work in some cases of broader autism-spectrum disorders.\u201d\n\nThe roots for the Novartis results began in 1982 when Stephen T. Warren, then a graduate student in genetics at Michigan State University, was looking for a job and something to research.\nThe results of the trial were something of a jumble until Novartis scientists noticed that patients who had a particular, undisclosed biological trait improved far more than others.\nWhen a doctor finally thought to do a fragile X test, Ms. Clapp and her husband, Dr. Michael Tranfaglia \u2014 both Harvard graduates with post-graduate degrees \u2014 researched the disease and came to two conclusions: fragile X was potentially treatable; and only about five researchers in the world were working toward a cure.\nSure enough, mice, fish and fruit flies that through genetic engineering were made to have fragile X seemed to become normal when given Dr. Bear\u2019s compound.\nThe predictions were premature because, like most of genetic research, discovering how the flawed gene caused disease was far harder than anticipated and required multiple leaps in neurology and biology.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "While the story does collect feedback from a number of independent expert sources, we think the way these sources were used was inappropriate and potentially misleading. The reporter seems to have approached many of the sources\u00a0and asked them to comment\u2013 without the benefit of any actual data\u2013on\u00a0the reporter\u2019s second-hand description of the apparent positive results of Novartis\u2019s research. The sources all respond with a variation on, \"Wow, that sounds\u00a0wonderful.\" And really, who wouldn\u2019t say the same thing? Nobody doubts\u00a0that a drug effective for fragile X syndrome would represent a huge\u00a0medical breakthrough. But the\u00a0more important question\u00a0prompted by the\u00a0article is whether such a breakthrough has in fact\u00a0occurred.\u00a0Although there are some cautions and caveats sprinkled throughout the article, we think the extremely positive tone of the expert quotes far outweighs these nuggets of restraint. What bears repeating (and what we\u00a0think\u00a0gets lost in this story)\u00a0is that\u00a0these experts are enthusiastic about the concept of an effective treatment; they are not endorsing\u00a0Novartis\u2019s\u00a0claim\u00a0that the drug caused \"clear improvements\" in behavior. \u00a0", "answer": 0}, {"article": "\"So we thought, 'What if we change that by injecting the therapy drug into the metastatic lesions and change the microenvironment of the cancer?'\nThe research was an early-stage study, conducted to test the side effects and best dosage of a potential new combined therapy, and the findings were published today in the journal Cancer Discovery.\nThe study was funded by Dynavax Technologies Corp., which provided SD-101.\nThe research showed that using the immunotherapy drug pembrolizumab and the experimental agent SD-101, a sequence of nucleic acids that mimics a bacterial infection, altered the microenvironment around the tumor in a way that enabled the immune system to more effectively attack the cancer.\nSeven of those nine had a positive response to the drug combination, including two for whom the tumors disappeared completely.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "This information is included in the release.", "answer": 1}, {"article": "This didn't stop MS.\"\n\n\"But, this is extremely hopeful research,\" he added.\nIf the experimental medication is eventually approved for use, it would be only the second oral MS drug available to patients, alongside a number of long-standing injectable options.\nThe study found that to date, the new drug appears to be both safe and well-tolerated.\n\"And with the one oral option we have today, there has been a lot of concern over a possible risk for immune suppression and also an increased risk for cancer,\" added Zamvil, who was not a part of the current study team.\nThe current research was funded by Teva Pharmaceuticals, the maker of laquinimod.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes two independent experts, and makes it clear that the study was funded by the maker of the drug being studied. \u201cThe current research was funded by Teva Pharmaceuticals, the maker of laquinimod,\u201d it says.", "answer": 1}, {"article": "\"It appears that women who reported taking prenatal vitamins starting three months prior to conception and through the first month after conception seem to have a reduced chance their child will develop autism ,\" says study researcher Irva Hertz-Picciotto, PhD, professor of epidemiology and environmental health at the MIND Institute and Department of Public Health, University of California, Davis.\nExactly why the prenatal vitamins may protect against autism is not clear, she says.\nThe risk rose if the mothers or the children had a high-risk gene form.\nStill, she says, the finding points to a gene-environment interaction that may possibly help explain some cases of autism.\nAll were enrolled in the CHARGE study (CHildhood Autism Risks from Genetics and Environment) from 2003 to 2009.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes an independent expert who was not involved with the research and who is identified as working for an advocacy group. There don\u2019t seem to be any other potential conflicts to disclose.", "answer": 1}, {"article": "Some 68% of the country is either overweight or obese, but there\u2019s not much clinical evidence on the best way to lose weight, outside of research on bariatric surgery. (True, \u201cEat less and exercise more\u201d is great advice if you can manage to follow it, but public-health authorities have repeated that line until they\u2019re blue in the face and as a population we\u2019ve only gotten fatter.)\n\nResearch presented over the weekend at the annual meeting of the Obesity Society and published online in the Journal of the American Medical Association suggests a few specific strategies that may help \u2026", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story does not quote any \"live\" sources, but it does make good use of an editorial that accompanied the study. It also points out that the study was finded by diet giant Jenny Craig and that the editorial writer, Rena Wing, a professor of psychiatry at Brown University called for \"cost-effectiveness studies, conducted by researchers without any financial ties to the companies involved, that compare different commercial programs with each other.\"", "answer": 1}, {"article": "National Jewish Health is the leading respiratory hospital in the nation.\nExperts say there is more research to be done, but that the goal of the trial is to discover the best combination of bacteria to clear eczema from the skin and then make it available to patients as a prescription cream.\nResearchers hope that using the bacteria-infused cream will offer a long-term solution where other treatments fall short.\nA new clinical trial is testing a natural treatment that researchers hope will provide a long-term solution for those dealing with the dry, itchy and painful skin that comes with chronic eczema.\nWhile it may seem counterintuitive to treat bacteria with more bacteria, experts say this approach seeks to restore the natural microbial balance of healthy skin.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "Funding sources for this clinical trial are not mentioned. Potential conflicts of interest are also not addressed and this could be relevant since a quick check of the lead author on Dollars for Docs reveals multiple sources of industry funding in the past.", "answer": 0}, {"article": "For more on aspirin, visit the National Institutes of Health.\nThe potential impact of aspirin on pancreatic, stomach and brain cancer death rates was more problematic to gauge, the authors noted, due to the relative paucity of deaths from those specific diseases.\nAnd while cautioning that more research is necessary to build on this \"proof of principle,\" the authors suggested that people who embark on a long-term, low-dose aspirin regimen in their late 40s and 50s are probably the ones who stand to benefit the most.\nBut the study's lead author, Prof. Peter Rothwell from John Radcliffe Hospital and the University of Oxford, stressed that \"these results do not mean that all adults should immediately start taking aspirin.\"\nThe current observations follow prior research conducted by the same study team, which reported in October that a long-term regimen of low-dose aspirin appears to shave the risk of dying from colorectal cancer by a third.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story includes comments from an independent cancer expert. That\u2019s the most important factor in this case, so we will pass this story on this criterion. However, while the study itself did not receive outside funding, readers should have been told that some of the authors have had consulting relationships with pharmaceutical companies.", "answer": 1}, {"article": "The Site is down for maintenance.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "There was an important voice added from a breast cancer survivor.\nBut there was no independent expert perspective added.", "answer": 0}, {"article": "Women ages 50-59 had 13,288 mammograms, 1,659 callbacks (12.5% recall rate), 371 biopsies, and 103 cancers detected, while women ages 60-69 had 12,119 mammograms, 1,239 callbacks (10.2% recall rate), 302 biopsies and 89 cancers detected.\nBy adding the women ages 40-49 to the screening population of 50 and over, the overall callback rate increased 1.5%, the biopsy rate increased 0.1% and 19.3% more cancers were detected.\nMore than 41,000 screening mammography exams were examined for callbacks and recall rate, biopsies performed, cancers detected, and sensitivity and specificity of screening mammography.\nOverall, 41,028 mammograms were performed with 5,196 callbacks (12.7% recall rate), 1,164 biopsies, and 326 cancers detected.\nThe study to be presented by Abid Irshad of the Medical University of South Carolina examined the effectiveness of screening mammography between ages 40-49 in comparison to age groups 50-59 and 60-69.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The news release did not mention anything about funding sources or conflicts of interest for the study. Just because a radiology society put out a study that proposed using more radiology procedures doesn\u2019t mean that there was a conflict of interest; but without disclosures from the study, we can\u2019t be sure.", "answer": 0}, {"article": "\u201cMy nightmare was that nothing would be different from the placebo group, and there would be nothing of interest to talk about,\u201d he says.\nI think resveratrol is an engaging target that\u2019s very interesting and could be pharmacologically manipulated to develop a treatment.\u201d\n\nMORE: Red Wine Not That Healthy After All, Study Shows\n\nThe resveratrol group showed no change in the levels of a protein that builds up in the brains of Alzheimer\u2019s patients.\nIn what the authors describe as the largest and longest study of resveratrol in people with mild to moderate Alzheimer\u2019s disease, there\u2019s encouraging news that the component, which is found in red wine, grapes and dark chocolate, may keep the disease from progressing.\nThe amounts of resveratrol in the purified doses that the participants took were extremely high and beyond those found on the market currently \u2014 around what would be contained in about 1,000 bottles of red wine.\nWe need more studies to see if it really does have benefit and then it could be turned into more effective drugs that can better target Alzheimer\u2019s.\u201d\n\nCorrection: The original version of this story misstated that all the participants were men.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "While several of the study authors have ties to the pharmaceutical industry, it\u2019s not clear whether any of those companies are developing resveratrol-based drugs or supplements, and the study itself was funded by the NIH. Regardless, the story does lack input from any experts who weren\u2019t involved in the study, which is necessary to meet our standard here. The story would have been much stronger if it had included outside experts who could have placed the work in context and helped readers understand how this work fits into the broader scheme of Alzheimer\u2019s research and treatment.", "answer": 0}, {"article": "Learning skills for positive emotions result in less HIV in blood and less anti-depressant use\n\u2022 Positive emotions are possible even with stress of chronic health problems\n\u2022 Men using positive emotion skills learned to cope with their stress, while control group went on anti-depressants\n\nCHICAGO --- When individuals recently diagnosed with HIV were coached to practice skills to help them experience positive emotions, the result was less HIV in their blood and lower antidepressant use, reports a new Northwestern Medicine study.\nThe HIV study is part of a larger body of positive affect research being conducted by Moskowitz.\nThis is believed to be the first test of a positive emotion intervention in people newly diagnosed with HIV.\nBased on the study results, the intervention is promising for people in the initial stages of adjustment to any serious chronic illness.\nThe positive emotion intervention also improved mental health.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release noted the grants that supported the research. The study didn\u2019t note any financial conflicts of interest. ", "answer": 1}, {"article": "According to the Skin Cancer Foundation, metastatic melanoma accounts for only about 1 percent of skin cancer cases but causes the majority of skin cancer deaths.\n\"Based on this study, it appears that patients with advanced melanoma who have their disease completely removed by surgery should go on to receive additional therapy with Opdivo,\" said Dr. Gary Deutsch.\nThe international study was funded by Opdivo's maker, Bristol-Myers Squibb, and included more than 900 patients with stage III and stage IV melanoma.\nOne cancer surgeon who reviewed the findings was impressed.\nAll underwent surgery for their cancer before they began treatment with either Opdivo (nivolumab) or Yervoy (ipilimumab), the drug that's the current standard of care.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story tells readers in the second paragraph that the study was funded by Bristol-Myers Squibb, which markets Opdivo. We like that the story places that information front and center. In addition, the story incorporates input from two independent sources.", "answer": 1}, {"article": "Imaging equipment makers such as GE Healthcare, Siemens, Philips and Toshiba Medical Systems are working to develop low-dose CT scanners.\nRedberg, who wrote a commentary on the studies, said U.S. doctors\u2019 enthusiasm for the tests has led to an explosion in their use that is putting patients at risk.\nThe findings, published in the Archives of Internal Medicine, add to mounting evidence that Americans are overexposed to radiation from diagnostic tests, especially from a specialized kind of X-ray called a computed tomography, or CT, scan.\nThe researchers said efforts need to be taken to minimize CT radiation exposure, including reducing the number of unnecessary tests, cutting the dose per study, and standardizing the doses across facilities.\n\u201cWhat we learned is there is a significant amount of radiation with these CT scans, more than what we thought, and there is a significant number of cancers,\u201d said Dr. Rita Redberg, editor of the Archives of Internal Medicine, where the studies were published.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story does not quote sources other than the authors of the study and the journal editor. The story should have quoted independent experts who could have provided some perspective on the importance of these results.", "answer": 0}, {"article": "\"These are children who could have died from a teaspoon of milk before,\" Wood said.\nA mere sip would leave her vomiting and gasping for breath.\nThe strategy is being tested in a handful of small studies that are part of a surge of research in a field that for years showed little progress.\nNo one should try the approach on his own, because the treatments themselves can trigger potentially life-threatening reactions.\nBut even that can be helpful.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "A broad range of experts in the field and a funding agency spokesperson were all quoted as sources of information for this story.\u00a0 ", "answer": 1}, {"article": "Related: Common Knee Surgery May Not Help You\n\nOsteoarthritis can affect any joint when the cartilage wears off over time, often striking big joints like the knee, causing pain, swelling and stiffness.\nBecause it was just approved by the FDA in April, the treatment is not widely available yet, but pain centers across the country are beginning to offer it.\nMarketed as \"Coolief\", the procedure uses radio frequency to target and mute the nerves responsible for sending pain signals from the arthritic knee to the brain.\nSome of the reported risks from the procedure include bleeding and infection.\nFor some patients with structural problems of the knee, the procedure won't help, said pain specialist Dr. Edgar Ross, associate professor of anesthesia at Brigham and Women\u2019s Hospital.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story has several independent sources. However, the story missed a potential conflict of interest. According to ProPublica\u2019s Dollars for Docs database, one of the story sources consults for at least two major medical device companies that make products similar to the \u201cCoolief\u201d system described in the story. That source also received small amounts of cash (for food and beverages) from Halyard Health, which makes the Coolief system.", "answer": 0}, {"article": "You\u2019re shepherding a fixed amount of resources across a large population and trying to do it according to some sort of evidence-based system.\u201d\n\nKaiser Health News is an editorially independent program of the Henry J. Kaiser Family Foundation, a nonprofit, nonpartisan health policy research and communication organization not affiliated with Kaiser Permanente.\nThat 19-member panel voted 10 to 5 last year that studies of the treatment showed it to be as good as or better than usual care for depression.\n\u201cThe initial treatment with rTMS is $12,000: That\u2019s a lot of generic Prozac or Effexor,\u201d which are cost-effective antidepressants with long track records, said Joel Rubinstein, associate medical director of Harvard Pilgrim HealthCare, an insurer that does not cover rTMS.\nMagnetic stimulation is aimed at patients with such \u201ctreatment-resistant depression.\u201d\n\nSupporters say rTMS is worth the cost \u2014 between $6,000 and $12,000 for the four-to-six-week treatment \u2014 because it enables people such as Curtis to resume productive lives.\nSupporters such as those at TMS NeuroHealth say they are seeing better results than that among their patients, who can continue taking antidepressants along with their treatment.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story represents both sides of this debate fairly, with the perspective of advocates from the device industry balanced against that of insurer-affiliated skeptics who say the evidence is weak. The story failed to clear the bar, however, when reporting comments from a researcher at Brown University who has conducted studies of rTMS. Although her comments are cautious and raise important questions about the treatment, the story did not disclose that she has been a consultant to, and received grant support from, rTMS device manufacturers (as indicated in this slide set from a recent presentation). It would have been nice to hear from an expert with no meaningful financial stake in this issue.", "answer": 0}, {"article": "The use in spine surgery of bone-growth proteins like Medtronic Inc.\u2019s product Infuse has led to widespread nationwide increases in hospital charges ranging from 11% to 41% above conventional surgical costs, researchers found.\n\nThe researchers studied the results of a broad U.S. sample of 328,000 spine surgeries from 2002 through 2006. They report their findings this week in JAMA, the Journal of the American Medical Association.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The study uses only one live source, the study\u2019s lead author. This is insufficient. \nOne or two additional voices would have been able to put these findings in context and help readers understand what they might mean.\u00a0\nHaving said that, the reporter does get extra points for trying to contact a researcher with clear economic motivations to explain his conclusions, which differ from the current study\u2019s. ", "answer": 0}, {"article": "In MS, it\u2019s the fatty protective sheath around the nerves; in type-1 or juvenile diabetes it\u2019s cells in the pancreas that make insulin; in rheumatoid arthritis it\u2019s tissue in the joint.\nIt\u2019s a kind of introduction that familiarizes the T-cells with the body\u2019s normal cells.\nBut Miller says the experiment also seemed to show they were beginning to repair the patients\u2019 immune systems.\nThese new nanoparticles stopped the course of a MS-like disease in mice, the researchers found.\nBut polystyrene is no good to use in people.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "There are no independent sources in the story, and all the sources provide an overly optimistic view of the future for this research.", "answer": 0}, {"article": "Platelet-rich plasma (PRP) is blood that has been spun in a centrifuge to separate the blood cells.\n\u201cPRP is probably the best treatment for chronic refractory lateral epicondylitis if it is used after classical types of treatment like rest, braces, nonsteroidal anti inflammatory drugs, cortisone injections or physiotherapy have all failed,\u201d Thanasas said.\n\u201cThere is now a solution for patients suffering from unrelenting \u2018tennis elbow,\u2019\u201d said Christos Thanasas from Henry Dunant Hospital, Athens, who led the study.\nThe findings were published in The American Journal of Sports Medicine.\n\u201cWhole blood treatment is a god alternative in remote areas or in health systems that do not support financially the use of PRP,\u201d he told Reuters Health in an email.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story only relied on a single source.", "answer": 0}, {"article": "BMI is a calculation of body fat based on height and weight, and a BMI of more than 30 is considered obese.\nCaution is vital when using any drug that has been approved for one condition for another, Sandon said.\nPsychological factors or lifestyle factors may play a role, he said.\nThe authors said such side effects were typically \"mild.\"\nThey concluded that the higher-dose zonisamide showed promise as a weight-loss aid, but advised clinicians to carefully weigh the pros and cons on a patient-by-patient basis.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story is almost entirely reliant on one source, the lead author of the story. It does quote one independent expert, but it\u2019s at the very end of the story and, in effect, is an endorsement of the study\u2019s findings. We are certain that other weight loss experts would have had more insightful or critical comments to make.", "answer": 0}, {"article": "About the American College of Surgeons\n\nThe American College of Surgeons is a scientific and educational organization of surgeons that was founded in 1913 to raise the standards of surgical practice and improve the quality of care for surgical patients.\n\"We found that laparoscopic surgery is associated with significantly lower costs.\nAlong with discovering that the use of laparoscopy for the surgical treatment of GERD has increased significantly in the last decade, the researchers also found that, on average, the minimally invasive approach reduced length of hospital stay by approximately two days, and open operations were more than $9,000 more expensive than minimally invasive procedures.\n\"Subsequently, the rate increased, but 15 percent of all anti-reflux operations were still being performed through an open approach in 2013.\nThe study showed that the rate of laparoscopic procedures increased from 24.8 percent in 2000 to 84.3 percent in 2013.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release does not list any funding source for the research and the published study notes that authors had \u201cnothing to disclose.\u201d\u00a0 We\u2019ll rate this not applicable since this is an examination of existing data, and there may have been no additional outside funding.", "answer": 2}, {"article": "The average daily dose of insulin dropped almost 39 percent after 12 weeks for the group with some beta cell function and 25 percent in those with no beta cell function, suggesting that the group with no beta cell function now produced insulin.\nThis was an initial clinical trial designed to test for safety.\nBoth experts said the treatment appears safe, with no risk of rejection.\nResults of the study were published online Jan. 9 in the journal BMC Medicine.\nAlthough the treatment didn't wean anyone off insulin completely, average blood sugar levels dropped significantly, which would reduce the risk of long-term complications.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "This story includes important context from an independent source. There is no discussion of any potential conflicts of interest of the researchers, but lacking any clear evidence of conflicts, we will give the story a passing grade. However, at least one online biography of the lead authors mentions that he holds several patents. If he or any of the authors own patents or other rights to treatments ultimately developed from this research, readers should be informed. The story did not report that the trial was funded by the University of Illinois (according to the trial registration: http://clinicaltrials.gov/ct2/show/NCT01350219). While academic institution funding may seem benign, many universities are actively engaged in licensing their discoveries or even creating companies to develop and market products of their labs, so even this source of funding may raise questions about financial entanglements.", "answer": 1}, {"article": "The study was supported by the Andrew Sabin Family Fellowship Program; the American Association for Cancer Research \u2013 Stand Up to Cancer; the National Institutes of Health (CA219896-01A1, HL124112); the Cancer Prevention & Research Institute of Texas; and the Melanoma Moon Shot\u2122, part of MD Anderson\u2019s Moon Shots Program\u2122, a collaborative effort to accelerate the development of scientific discoveries into clinical advances that save patients\u2019 lives\n\nIn addition to Wang, other MD Anderson authors include: Diana Wiesnoski, Christopher Sanchez, and Chia-Chi Chang, Ph.D., all of Genomic Medicine; Beth Helmink, M.D., Ph.D., and Vancheswaran Gopalakrishnan, Ph.D., both of Surgical Oncology; Hamzah Abu-Sbeih, M.D., Gottumukkala Raju, M.D., and John Stroehlein, M.D., all of Gastroenterology, Hepatology & Nutrition; Edwin Parra, M.D., Ph.D., and Alejandro Francisco-Cruz, Ph.D., both of Translational Molecular Pathology; Matthew Campbell, M.D., Jianjun Gao, M.D., Ph.D., and Sumit Subudhi, M.D., Ph.D., all of Genitourinary Medical Oncology; Dipen Maru, M.D., of Pathology; Jorge Blando, DVM, and James Allison, Ph.D., both of Immunology; Padmanee Sharma, M.D., Ph.D., of Genitourinary Medical Oncology and Immunology; Michael Tetzlaff, M.D., Ph.D., of Translational Molecular Pathology and Pathology; Jennifer Wargo, M.D., of Genomic Medicine and Surgical Oncology; and Robert Jenq, M.D., of Genomic Medicine and Stem Cell Transplantation.\nThe study from The University of Texas MD Anderson Cancer Center, which includes two patients, suggests fecal microbiota transplantation (FMT) is worth investigating in clinical trials as a therapy for this common side effect of immunotherapy.\nHowever, these treatments are often associated with significant immune-related toxicities.\nAdditionally, distinct new populations of bacterial species were evident in these patients following FMT compared to pre-treatment samples, including several species known to be protective or reduce inflammation.\nWith endoscopic evaluation before and after treatment, both patients displayed significant improvements in inflammation and ulcerations, including a reduction of inflammatory immune cells.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release does identify funding sources, but it does not illuminate possible conflicts of interest.\u00a0 Admittedly, this would be hard to do given the large number of coauthors.\u00a0 But a section on \u201ccompeting interests\u201d in the Nature Medicine article that jump-started this release does indicate that some of the coauthors have a commercial interest in the success of microbiome treatment applications.", "answer": 0}, {"article": "Jan. 4, 2013 -- A new study from Australia may offer a new way of identifying people at risk of glaucoma years before vision loss happens.\nThe study appears in the latest issue of the journal Ophthalmology.\nEarly detection is key, but without regular eye exams, most people don\u2019t know they have a problem, says ophthalmologist Andrew Iwach, MD.\nIn the study, researchers were able to predict who was at increased risk of developing the eye disease with some accuracy by measuring blood vessel thickness in the retinas of study participants using a computer-based imaging tool.\nThose with the narrowest vessels at the beginning of the study were four times more likely to have developed glaucoma a decade later.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The closing comment from an independent eye surgeon provided some necessary \u2013 albeit late and brief \u2013 perspective.", "answer": 1}, {"article": "Omega-3 fatty acids are unsaturated fats found in most fish, but especially in fatty fish that live in cold seawater, such as salmon and herring.\nThe research described in Quick Study comes from credible, peer-reviewed journals.\nCAVEATS Most participants were white.\nMight fish consumption help the brain, too?\nWHO MAY BE AFFECTED?\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "No independent source was quoted. An extra two dozen words may have done the trick.", "answer": 0}, {"article": "In men, T plays a key role in the development of male reproductive tissues as well as promoting secondary sexual characteristics such as increased muscle and bone mass and growth of body hair.\nIn the non-treated control group, there were 21 deaths, 19 of which were related to CV events.\nThese findings appear online in the Journal of Cardiovascular Pharmacology and Therapeutics.\n\"The low CV events observed in the T-group compared to the untreated (control) group strongly suggest that TTh is protective.\nAccording to the researchers, long-term TTh in men with hypogonadism appears to be an effective approach to achieve sustained improvements in cardiometabolic function and reduces the risk of CV events.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "A study funder, Bayer Pharma, is not acknowledged although several coauthors are identified as receiving compensation from the company. Missing entirely from the press release is an acknowledgement that Bayer Pharma markets hormone replacement drugs to treat low levels of testosterone.", "answer": 0}, {"article": "The editorial was written by Dr. Philip Greenland of Northwestern University, who is also a senior editor of JAMA, and Dr. Michael S. Lauer of the National Heart, Lung and Blood Institute.\nThe other suggests that treating people based on the new guidelines would be cost-effective, even with the tremendously increased use of statins.\nBut they could help dispel some of the criticism of the new guidelines and strengthen the position of those who contend treatment should be extended to more people.\n\u201cThere is no longer any question as to whether to offer treatment with statins for patients for primary prevention, and there should now be fewer questions about how to treat and in whom,\u201d said an editorial that accompanied the publication of the studies in JAMA, a journal of the American Medical Association.\nThe new studies are not large clinical trials that will definitively settle the matter of whether to expand drug treatment to millions more people in hopes of preventing cardiovascular disease, the leading killer of Americans.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story sought out and made good use of independent sources. It mentions that the guidelines were widely criticized and links to some printed criticisms made at the time. It quotes a variety of supportive and critical researchers regarding their opinions on the new research.", "answer": 1}, {"article": "(Reuters Health) - People struggling with irritable bowel syndrome (IBS) might feel better with antidepressants or psychotherapy, a recent study suggests.\nStill, a psychological evaluation may make sense for IBS patients because it\u2019s possible their symptoms might be a byproduct of untreated depression, said Dr. Agnieszka Kulak-Bejda, a psychiatry researcher at the Medical University of Bia\u0142ystok in Poland who wasn\u2019t involved in the study.\nAlthough the use of antidepressants is common among IBS patients, psychotherapy is not, the study authors note.\nAntidepressants may work better for certain types of IBS, and the study findings also suggest that the type of medication may matter, Kulak-Bejda said by email.\nA family of medicines known as tricyclic antidepressants were more effective at relieving global symptoms of IBS, the analysis found.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story incorporates input from two third-party experts. The story does not speak to potential conflicts of interest, which is a shortcoming. We found no potential conflicts to report, but think it is worth making that clear in a story.", "answer": 1}, {"article": "Dr. Jeffrey Tice, an internist at the University of California, San Francisco, who wrote an editorial accompanying the study, said: \"With hormones, we really were thinking we were preventing a lot of diseases and it was good for the long term.\nThere were only two studies for Effexor, just one of which suggested it might help.\nShe took a cautious view because she and her colleagues found that there was relatively little reliable data on using the drugs for hot flashes.\nBut Dr. Tice warned that the drugs should not be used long term.\nAll the nonhormonal drugs have side effects.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The study was not funded by any of the drug manufacturers with medications under study in the review. Principal investigators have no financial ties to drugs mentioned in the study, though the story does not mention this. ", "answer": 1}, {"article": "increases at age 4, although no cognitive benefit was seen in infants or 7-year-olds.\nThat study\u2019s lead author, Dr. Ingrid Helland of Oslo University Hospital, said that perhaps the benefit shown at age 4 existed at 7 but was difficult to identify amid other developmental factors.\nThe lead researcher, Dr. Maria Makrides of the University of Adelaide in Australia, said this suggested that full-term babies already get enough DHA in the womb, and that \u201cthere\u2019s no extra boost\u201d from getting more.\nShe said babies in her study might have received more DHA than those in this study.\nHe said more research was needed, but for now, \u201cI think the market is running way out in front of the science.\u201d\n\nScientists agree that DHA, naturally transmitted to a fetus through the placenta in the last half of pregnancy, is important, probably to visual and brain development.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "There were several independent sources quoted/cited in the story. ", "answer": 1}, {"article": "In addition, people can obtain folic acid from breads, cereals and other grain products enriched with folic acid, as well as folic acid supplements.\nHowever, there is no scientific evidence that taking folate supplements will be beneficial, Armstrong noted.\nNone of the other factors they examined accounted for their finding, Nilsson's team noted.\nIn fact, folate deficiencies may be involved in the development of autism, he added.\nIn previous studies, folic acid levels have been linked to mental ability; however, until now this had not been linked with improved school performance, the study authors said.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Quotes from a clinician without apparent ties to the story were included in this story.", "answer": 1}, {"article": "\"Transfer between hospitals takes a lot of time,\" said Turner.\nThis study was funded by Cerebrotech Medical Systems.\nThe researchers hope that the device will save valuable time -- especially important in stroke where time is brain -- when it is deployed with emergency medical personnel in the field.\nIf so, the VIPS device could have widespread clinical implications, helping emergency personnel decide whether to take a patient to a comprehensive stroke center or a primary stroke center for treatment.\nThe VIPS device is made by Cerebrotech Medical Systems, which paid consultants to analyze the neuroimaging data independently.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release identifies the funding company, Cerebrotech Medical Systems, and notes that Cerebrotech \u201cpaid consultants to analyze the neuroimaging data independently.\u201d", "answer": 1}, {"article": "For instance, yoga may influence brain chemicals known as neurotransmitters (boosting levels of feel-good agents like serotonin), lower inflammation, reduce oxidative stress and produce a healthier balance of lipids and growth factors \u2014 just as other forms of exercise do.\nSome of the studies included in the analysis even suggested that yoga might affect the body in ways similar to antidepressants and psychotherapy.\nBut while the research is promising, yoga likely won\u2019t be a panacea for mental illness.\nThe researchers say there\u2019s enough evidence to warrant a larger study on the effects of yoga on mental health, and it should be considered as part of treatment for more disorders.\n\u201cMost individuals already know that yoga produces some kind of a calming effect.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Researchers tend to be optimistic about the treatments they are studying, and the study author quoted in this story is no different. That\u2019s why it\u2019s always a good idea to include an objective\u00a0perspective from an independent expert \u2014 something this story regrettably lacked.", "answer": 0}, {"article": "\"[The study is] one of the first studies that evaluated the role of Mediterranean diet on metabolic syndrome, and revealed a beneficial association- quite a big influence, taking into account that the Mediterranean diet is a non-pharmacological mean,\" said study author Demosthenes Panagiotakos, from the Department of Science of Dietetics-Nutrition at Harokopio University of Athens in Greece.\nThe Mediterranean diet isn't just a little extra olive oil, noted Dr. Robert Eckel, an endocrinologist and past president of the American Heart Association.\nThe study notes physical activity is also an important part in preventing the risk factors for the metabolic syndrome.\nThe syndrome is present when someone has three of those five risk factors.\nPanagiotakos concludes that this pattern of eating can be easily adopted by people of various cultures and populations.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Independent perspective provided by a past president of the American Heart Association.", "answer": 1}, {"article": "(Reuters Health) - When a migraine strikes, patients might one day be able to make the experience less painful by using a smartphone-controlled device to deliver mild electric shocks to their arm, a company-funded experiment suggests.\n\u201cAll stimulation treatments given so far have been in the head,\u201d said lead study author Dr. David Yarnitsky, an advisory board member for Theranica, the company developing the device.\nResearchers asked participants to put the device on their upper arm as soon as possible after the start of a migraine and use it for 20 minutes.\nIf the device works in larger trials and becomes widely available for migraine patients, it might offer an alternative for people who can\u2019t tolerate migraine drugs or an option patients could try in addition to medication when they don\u2019t get enough pain relief from drugs alone, Schoenen said.\nOne shortcoming of the current study is that researchers didn\u2019t examine how long the pain relief lasts beyond two hours, Schoenen said by email.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story included cautionary comments from a neurology researcher, which helps balance and contextualize the study\u2019s results.\u00a0The story also disclosed that the study was \u201ccompany-funded\u201d and that the study\u2019s lead author is \u201can advisory board member for Theranica, the company developing the device.\u201d", "answer": 1}, {"article": "Compared with the 16% of people who didn't drink coffee at all, those who downed two or more cups each day were about 18% less likely to have died during the study period. In addition, those who drank just one to six cups of coffee per week were 12% less likely to die. Both of these figures were calculated after taking into account known risk factors for early death, such as smoking (which is often paired with coffee drinking), diet and body mass index.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story includes perspective from an editorial that accompanied the studies in the journal, the Annals of Internal Medicine. And that\u2019s enough for a satisfactory grade. Reaching out to more sources, and actually talking to experts in this field, might have turned up additional insights worth sharing with readers.", "answer": 1}, {"article": "But most of the success so far has been with blood cancers like lymphomas and leukemias.\nIf the patient had not received the CAR T therapy, he likely would only have survived a few weeks after his cancer recurred, says Badie.\nBased on this man\u2019s case, his team is hoping to now inject not just the tumor site but also the ventricular space in the brain, since that may help control spread of the cancer.\nBadie is hoping to take advantage of this information and introduce immune cells with different tumor-targeting proteins.\nBadie says it\u2019s not obvious why, but his analysis showed that these tumors did not contain much of the protein targeted by the CAR T cells that were injected.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "No outside sources were quoted, which is a vital aspect of any journalism regarding City of Hope Medical Center, which we\u2019ve called out for its \u201cmiracle mongering.\u201d An independent source\u2013such as we saw in our STAT review\u2013can be a vital way to ascertain\u00a0differing viewpoints on and help keep expectations in check.", "answer": 0}, {"article": "MS can cause many symptoms, including blurred vision, loss of balance, poor coordination, slurred speech, tremors, numbness, extreme fatigue, problems with memory and concentration, paralysis and blindness.\nThose deaths are a major concern, one neurologist said, because MS is not in itself life-threatening.\nA trial that compares stem cell transplants with other therapies to see whether stem cell transplants can become a treatment for patients who have progressive MS is about to start, added Racke, who co-authored an editorial that accompanied the study.\nThe researchers think these deaths were most likely due to the transplant technology used before 2006, which has since improved.\nBut the treatment can be risky because the patient's immune system has to be wiped out before the stem cells are transplanted, the researchers said.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story includes input from one independent source (who highlighted the ethical concerns regarding treatment-related deaths for a nonfatal disease). He does not appear to have any relevant conflicts of interest.", "answer": 1}, {"article": "To learn more about breast cancer surgery, visit the American Cancer Society.\nThe expected cost of the MarginProbe in the United States, if approved, is not yet known, said Michael Graffeo, a spokesman for its maker, Dune Medical Devices.\nIn June, the radiation-free device won the blessing of a U.S. Food and Drug Administration advisory panel.\nLooking at the volume of tissue excised, the researchers said not much more tissue was removed when the device was used compared to tissue removed in the initial and subsequent surgeries among the control-group patients, Boolbol said.\nIf the results are repeated in larger studies, it could be a welcome addition to doctors' techniques, she said.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "While the story does quote a respected\u00a0independent source about the need for additional studies, the story should have also indicated that the study was funded by Dune Medical Devices, the manufacturer of the MarginProbe device.", "answer": 0}, {"article": "\"We think it will be a very important tool in the toolbag of surgeons and physicians treating obesity and its co-morbidities,\" said Gregory S. Lea, senior vice president and chief financial officer of EnteroMedics. \"When patients leave the diet, counseling and drug world and have nothing more, they turn to surgical procedures, and only 1% to 2% of patients who might be eligible for bariatric surgery are getting it.\"", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "We commend the story for actually talking with two experts who are knowledgeable about the device and related research. That being said, these experts were a senior executive with the device manufacturer and a researcher who conducted some of the studies leading to development of the device. They both have a vested interest in the success of the device. The story would have been stronger if it had chosen to interview an outside expert in gastroenterology, endocrinology or a related specialty to give an unbiased perspective on the device.\nHealthNewsReviews.org offers a list of independent experts in many fields who are willing to provide an outside perspective on health news stories.", "answer": 0}, {"article": "The higher a person's insulin levels are, the more likely they are to have or develop insulin resistance, which can increase blood sugar levels and diabetes risk.\nThe study authors had no part in which procedures the teens received.\nThe findings are important because many of the participants in this study likely already had some level of cardiac damage, such as thickened arteries or heart walls, says Geetha Raghuveer, a pediatric cardiologist at Children's Mercy Kansas City in Missouri who was not involved in the study.\nIn fact, the majority of the participants \u2014 83 percent \u2014 had only one or no risk factors three years after their surgeries.\nPeople who have a gastric bypass often have nutritional and vitamin deficiencies, Lenhard said.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story includes two sources who were not part of the study.", "answer": 1}, {"article": "One week after surgery I was off the crutches, walking on my own,\" Wallace said.\nThe best candidates for the procedure are patients who still have some cartilage protecting their joint, but have somehow \"overloaded\" and injured the bone, causing swelling and pain, Hepinstall said.\nThose with full-blown bone-on-bone arthritis or joint pain caused by damage to the cartilage and ligaments will get little to no relief from the procedure, Vasileff said.\nThe procedure, called subchondroplasty, has been available to people with knee problems for years, Vasileff said.\nIt is much less invasive than a knee or hip replacement, and typically is performed on an outpatient basis, Vasileff said.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Two doctors and one patient served as sources of information for this news story. One of the doctors gave important commentary on the lack of evidence, which was good. However, according to Dollars for Docs, both doctors have received money from orthopedic device makers, some of which make products for this procedure. That should have been disclosed.", "answer": 0}, {"article": "\u201cIt\u2019s like you\u2019re possessed,\u201d said Lorie Novak, who has suffered from chronic migraines since childhood.\nBut the companies\u2019 fortunes are intertwined, he said, and \u201cthe class only wins if headache care in America improves.\u201d\n\nAiming to prevent migraines before they start\n\nThere\u2019s plenty of room for improvement.\nTargeting CGRP is not a particularly new idea.\nScientists haven\u2019t nailed down just how the protein affects migraines, but they\u2019re sure about two things: CGRP levels rocket up when headaches attack and normalize when they go away.\nThat medication, Topamax, has been dubbed dubbed \u201cSleepomax\u201d by doctors and patients because it\u2019s also a heavy sedative.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story makes clear that four large drug companies are working to develop drugs, leading to an easy inference that the companies are funding the research. Among the story\u2019s sources, those working for the companies are so identified and others are characterized as unaffiliated with the companies. Nothing in the story broaches possible conflicts of interest.", "answer": 1}, {"article": "\"My reaction was, 'Well, you smoked for 30 years.\nLike many patients his age, he didn't expect there would be any effective treatment.\nAnd, after five years, almost 9 out of 10 patients were alive and cancer free.\nAnd he found that a surprising number of these older patients did quite well.\nThis was the case for Morton Pollner, who is one of Adusumilli's patients.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story included an independent source and we didn\u2019t note any potential conflicts of interest.", "answer": 1}, {"article": "In the case of microablative fractional CO2 laser surgery, a series of microscopic laser beams using fractionated energy penetrate the skin to remove old and damaged skin cells, intended to rebuild the vaginal pathway.\n\"This study adds to the literature on vaginal laser therapy for GSM.\nStudy results are published in the article \"Microablative fractional CO2 laser for the genitourinary syndrome of menopause: up to 12-month results.\"\nThe results of this small, retrospective, non-sham-controlled study demonstrated that this type of laser surgery was particularly effective in reducing the intensity of dyspareunia (painful sex) and dryness.\n\"Until more data are available, all treatment options, including lubricants, vaginal moisturizers, and FDA-approved vaginal and systemic hormone therapies, should be discussed with women who suffer from GSM to determine the best treatment option for them.\"\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "Funding for the study is not included.\nAlso relevant for readers, but not mentioned, is that two of the authors have financial ties to the company that produces the laser tested in this study.\u00a0Both authors have been expert witnesses for the laser company, suggesting a higher degree of approval of the therapy and potential for bias in the way the study is done.\nEqually relevant is that the National Menopause Society (NAMS)\u00a0 \u2014 which authored the news release \u2014 receives corporate support from about a dozen biotechnology companies, many that sell treatments targeted at GSM.\u00a0 Also, about three-fourths of the NAMS board have disclosed relationships with industry.", "answer": 0}, {"article": "As a leading institution funded by the National Cancer Institute, Mayo Clinic Cancer Center conducts basic, clinical and population science research, translating discoveries into improved methods for prevention, diagnosis, prognosis and therapy.\nDr. McBane noted that cancer and cancer treatment can be associated with kidney injury, which can limit the drug's use further.\n\"As a class, these drugs have a number of advantages, including oral delivery, lack of interactions with foods or other medications, and the lack of a need for monitoring drug levels.\"\nTheir findings were presented at the annual meeting of the American Society of Hematology by Robert McBane II M.D., a Mayo Clinic cardiologist.\nHowever, it was unclear whether these drugs could be used safely in cancer patients until now.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The news release does not mention any conflict of interests or funding sources. The website with the conference presentation abstract lists that the lead author received research funding from pharmaceutical company Pfizer.", "answer": 0}, {"article": "EULAR aims to promote, stimulate and support the research, prevention, and treatment of rheumatic diseases and the rehabilitation of those it affects.\nOf the 47 patients who reduced, then stopped their TNFi after six months, 45% (21/47) succeeded without flaring, and their final mean DAS28 score after stopping treatment was 2.2, demonstrating low disease activity.\n\"The optimal management of RA involves achieving the lowest possible disease activity - ideally remission, and then maintaining this level of control,\" said lead author, Dr. James Galloway, Department of Rheumatology, King's College Hospital NHS Foundation Trust, UK.\n\"Findings from our study have shown that adopting a TNFi dose reduction strategy can still meet this objective, with no compromise on symptom control for the patient and offering a more cost-effective option by substantially reducing the high drug costs associated with TNFi maintenance therapy.\"\nIn some cases however, patients maintained a clinical response after stopping the TNFi altogether.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "No mention is made in the news release of who funded the study or whether there were any conflicts of interest. The study\u2019s lead author, Dr. James Galloway, said in an email to HealthNewsReview.org that the work was funded by Arthritis Research UK, a charity. The study itself says the authors declared no conflicts of interest.", "answer": 0}, {"article": "Resveratrol is a naturally occurring compound found in foods such as red grapes, raspberries, dark chocolate and some red wines.\nThe results, published online today in Neurology, \"are very interesting,\" says the study's principal investigator, R. Scott Turner, MD, PhD, director of the Memory Disorders Program at Georgetown University Medical Center.\nAn \"investigational new drug\" application was required by the U.S. Food and Drug Administration to test the pure synthetic (pharmaceutical-grade) resveratrol in the study.\nTurner, who treats patients at MedStar Georgetown University Hospital, cautions that the findings cannot be used to recommend resveratrol.\nGUMC was one of 21 participating medical centers across the U.S.\n\nFurther studies, including analysis of frozen blood and cerebrospinal fluid taken from patients, are underway to test possible drug mechanisms.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The news release discloses the funding source, which was the National Institute on Aging. The study\u2019s principal investigator R. Scott Turner, according to the disclosure statement attached to the original journal article, states he has received research support from Ceregene, Eli Lilly, Merck, Biogen Idec, Toyama, Elan/Transition Therapeutics and Pfizer, as well as the NIH and the DOD.\u00a0The news release doesn\u2019t list these disclosures, and says only that that Dr. Turner \u201creports no personal financial interests related to the study.\u201d\nWe\u2019d argue that it would have been better to list those disclosures in the news release, since they were deemed important enough to include the journal manuscript. But since we couldn\u2019t easily find any indication that these companies are developing resveratrol-based drugs \u2014 which would be a clear conflict of interest \u2014 we\u2019ll give the benefit of the doubt and rule this Satisfactory.", "answer": 1}, {"article": "Several companies, including one owned by Koniver, make herbal combinations.\nGiven these two rejections, it could be a while before another pharmaceutical company decides to sink money into developing a new drug for women with sexual problems.\nIn fact, for nearly all alternative practices there are no large-scale studies saying if they work or not.\nBut in the absence of a drug to help women with sexual problems, here's what's recommended by some practitioners.\n(CNN) -- Losing interest in sex would be unfortunate for most people, but for Linda Poelzl it was a professional hazard.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "When there are two sides to an issue, it\u2019s not enough to source a story with three views from the same side, as this story did. While it is undeniable that many patients find great comfort and benefit from alternative medicine approaches\u00a0such as those discussed in this article, it is equally clear that many of these treatments have very little\u00a0evidence to support their use, and have the potential to cause harm. Of course, the same is true for many \"conventional\" medical practices, which is why we always think it\u2019s a good idea to include at\u00a0least one truly independent source to comment on claims made in a health story. \u00a0", "answer": 0}, {"article": "The resource you are looking for might have been removed, had its name changed, or is temporarily unavailable.", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "While readers can reasonably assume that the author of the materials will be paid a share of the sales proceeds, the release should have specifically disclosed whether the celebrity quoted in the release (Lou Pinella) was paid for his endorsement.", "answer": 0}, {"article": "N-acetylcysteine reduced PTSD symptoms, cravings, and depression in veterans with PTSD and substance use disorder in a randomized controlled pilot trial conducted at the Medical University of South Carolina and the Ralph H. Johnson VA Medical Center\n\nN-acetylcysteine, when combined with group cognitive behavioral therapy (CBT), reduced symptoms of posttraumatic stress disorder (PTSD), cravings, and depression significantly more than CBT alone in veterans with co-occurring PTSD and substance use disorder, a particularly difficult-to-treat population, according to the findings of a randomized controlled pilot trial conducted by researchers at the Medical University of South Carolina (MUSC) and the Ralph H. Johnson VA Medical Center.\nThis trial is the first to use NAC as a pharmacotherapy for PTSD and a broad range of SUDs.\nCurrently, there are no well-explored pharmacological treatments for patients with co-occurring PTSD/SUD.\nOf the veterans enrolled in the trial, 83% completed it, a very high rate for this difficult-to-treat population.\nThe threshold CAPS score for diagnosis of PTSD is 50.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release clearly states the funding sources and it would be very unlikely that these researchers would have a financial interest in the product under study since it is off-patent and generically available without a prescription.", "answer": 1}, {"article": "When the researchers used the longer Tao brush, they were able to detect endometrial cancer in all but 7% of the women who had the disease, and close to half of the ovarian cancers. Combined with the fact that these tests were performed with a mere swipe of the uterine wall, these measures of \u201csensitivity\u201d \u2014 the ability to detect cancers that are actually there \u2014 represent a major improvement over the screening tests currently available.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "This is the story\u2019s biggest shortcoming, as there are no independent sources, and it fails to note a number of significant financial conflicts of interest. The research funding appears to be spread among a number of foundations that wouldn\u2019t necessarily profit from PapSeek tests. However, the \u201ccompeting interests\u201d section details how 10 of the 37 authors stand to profit from the genes and tests used, including through patents, royalties, and equity \u2014 including five of the six corresponding authors.\nScientists having a financial stake in study is not uncommon, and doesn\u2019t necessarily weaken a study\u2019s results, but it should serve as a red flag to journalists to seek more outside expert opinions than normal. But the LA Times does not appear to have interviewed even one researcher not involved in the work, let alone without financial stakes in it. (Dr. Nickolas Papadopoulos, the only person quoted in the piece, is listed under several areas of stated competing interests in the study\u2019s notes.)\nThis information was easily found in the\u00a0news release.", "answer": 0}, {"article": "Bisphosphonates include such common drugs as Fosamax (alendronate), Boniva (ibandronate), Actonel (risedronate) and Reclast (zoledronic acid).\nA randomized trial is need to prove that bisphosphonates are protective against colorectal cancer, Rennert said.\n\"Results from the only other study of bisphosphonate use and colorectal cancer, a recent large study from the United Kingdom, do not support an important protective effect,\" Jacobs noted.\n\"The adverse effects profile is of major importance if bisphosphonates are going to be recommended for cancer prevention in healthy people,\" the study authors cautioned.\n\"The magnitude of the reduced risk is less important because this is an association study; however, it is very significant after controlling for a dozen other known risk factors,\" Rennert said.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Both stories quoted the exact same sources: the lead author and\u00a0Eric Jacobs, Strategic Director of Pharmacoepidemiology at the American Cancer Society. But both stories used their comments in very different ways. The Reuters Health story did not allow Rennert to run wild with enthusiasm. The HealthDay story did. For example, when the story notes that \u201cA randomized trial is needed to prove that bisphosphonates are protective against colorectal cancer, Rennert said.\u201d It follows that sobering bit of news up immediately with, \u201cIt should be relatively easy, as it seems that all that is needed is a year of treatment to see the effect,\u201d he said. Should be relatively easy? Ask any drug company how much time it takes and what it costs to bring a drug to market and no one will tell you that clinical trials are easy. This is especially troubling given that a previous study just last year showed no benefit, and, remember, we are talking about just 41 women who appear to have staved off cancer by taking these drugs.", "answer": 1}, {"article": "As technologies and processes continue improve this is likely to be reduced,\" she continues.\nHe added, however, that the studies confirm the potential of cancer vaccines.\nWhile they are very small scale\u2014one was on six participants, the other 13\u2014the findings mean researchers can move ahead with the vaccines, which could potentially lead to new, more effective cancer treatments.\nCornelius Melief, from the Leiden University Medical Center, Netherlands, said in an accompanying News & Views article that controlled, randomized Phase II clinical trials will be needed to work out if the vaccines are effective.\nThese vaccines are not necessarily the future of personalized cancer treatment.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story incorporates insights from a few independent sources. This gives readers additional information about how the findings should be interpreted. However, no information is provided about potential conflicts of interest.", "answer": 1}, {"article": "By far, the lowest incidence of colorectal cancers was seen in pesco-vegetarians, people who eat fish at least once a month but eschew all other types of meat. Compared to omnivores, pesco-vegetarians were 43% less likely to be diagnosed with these cancers during the course of the study.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "There are no apparent conflicts of interest, but the story does not include input from any independent sources.", "answer": 0}, {"article": "Some critics say Medicare would not be doing a review of a drug already approved by the F.D.A.\nHowever, the panel gave very low scores to evidence that the drug would help prostate cancer patients other than the type who participated in the clinical trial, which were men with advanced cancer, but no or minimal symptoms.\nDr. Jacques said he ordered the review after being contacted by federal lawmakers questioning why their constituents could not get the drug.\nHowever, Dr. Smith said he doubted that was the case because there were signs the drug also controlled tumors outside the bones.\nAnother investigator in the trial, Dr. David C. Smith of the University of Michigan, said he could not believe it when the bone scan of one patient, who previously had widespread cancer in his bones, came back completely clean.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quoted at least one clinical expert who did not appear to have ties to the study reported on or the company that makes the drug. It would have greatly improved this story if insight from an expert on prostate cancer, especially castration-resistant prostate cancer had provided a context for evaluating the benefit of the drugs reported on \u2013 including quality of life issues.", "answer": 1}, {"article": "I was in New York last week, and the air was also not very clean.\u201d\n\nThe protective effect of ectoine was discovered by Prof Jean Krutmann and colleagues at the Leibniz Research Institute for Environmental Medicine, while investigating whether the molecule could protect skin against sun damage.\nBilstein said the inhaler could be useful around the world, as particulate air pollution is not just a European problem: \u201cEspecially in Asia \u2013 China in particular \u2013 the demand for such a product is even higher.\nRussell, who also lectures at Imperial College and Oxford University, said it might also be useful for the treatment of asthma, COPD and other lung diseases, not only prevention.\n\u201cThe point that it can prevent the lung inflammation induced by ultrafine particles is established \u2013 there is no more doubt,\u201d Krutmann said.\nBitop funded a series of studies, now published in prominent scientific journals.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Comments from one independent source are provided and the potential conflicts of interest of Dr. Klutman and Bilstein are in part duly noted.", "answer": 1}, {"article": "And then there's the lengthy recovery ahead, a less than ideal situation to find yourself in.\"\nThe researchers are continuing to investigate the use of this drug to treat Dupuytren's disease in a phase 2b trial called the RIDD trial, which is currently running in Oxford and Edinburgh.\nIn conjunction with Professor Sir Ravinder Maini, Sir Marc identified TNF as a therapeutic target in patients with rheumatoid arthritis.\nThe team found that adalimumab (at a dose of 40mg formulated in 0.4ml) reduces expression of the fibrotic markers, -smooth muscle actin (-SMA) and type I procollagen, at 2 weeks post injection, suggesting this drug could be used to stop the growth of disease causing myofibroblast cells.\nThis randomised trial (phase 2a) recruited 28 patients with Dupuytren's disease who were scheduled to have surgery in Edinburgh to remove diseased tissue in their hand.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "This is a major weakness of the news release.\nAlthough sources of funding are included (Wellcome Trust, Department of Health, 180Therapeutics.com) in the release, it\u2019s not made clear that the two co-authors quoted have patents with 180Therapeutics related to this therapy.\nIn fact, the majority of the 17 authors listed on this study have financial ties to 180Therapeutics, a for-profit company focused solely on anti-TNF therapeutics (which the website mentions is a \u201c$30-billion annual drug market class\u201d).", "answer": 0}, {"article": "Researchers have two main theories on why light therapy works.\nThe researchers said enough clinical evidence now supports mental health professionals recommending light therapy as a treatment for depression.\nAlthough the light therapy helped many patients, it provided the most benefit to those who were also taking the antidepressant.\nBut now a study has found that light therapy also works in treating non-seasonal depression.\nExperts have known for some time that light therapy can improve the mood of people who feel especially down when the days get shorter and gloomier.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story included a quote from an independent source other than study authors, so we\u2019ll award a Satisfactory. However, it would not have taken much to find someone who would have raised some questions about the study and offered a note of caution or two.", "answer": 1}, {"article": "But are they receiving it?\n\u201cYet, such facts are being kept from adult consumers of legal tobacco/nicotine products, either by not informing or actively misinforming consumers.\nThis fear, however, is not based on actual evidence and cannot be used to suppress or otherwise keep the public uninformed of what is clearly known about the lower risks of these products,\u201d adds Kozlowski, PhD, one of the world\u2019s leading researchers on smoking behavior.\nA briefing posted on the site specifically states: \u201cCompared to tobacco products, electronic cigarettes are significantly safer.\u201d\n\nIn their paper, the researchers note that information on comparative risks is common for other products and activities, like over-the-counter medicines and even safety ratings of vehicles.\nIn fact, they found that the Mayo Clinic perpetuated a misrepresentation discovered in 2003 \u2014 erroneously informing visitors that smokeless tobacco was as dangerous as cigarettes.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "After years of reading stories about how Big Tobacco was behind many studies that questioned the danger posed by traditional cigarettes, a reader can be excused for thinking that, perhaps, the smokeless tobacco industry was funding the work published here. A look at the study shows that that was not the case, but few people reading the news release would get to that point. In cases where the index of suspicion is high, the news release would boost its own credibility if it was explicit that there were no conflicts of interest.", "answer": 0}, {"article": "I'll keep going as long as I can enjoy what's to be enjoyed.\u201d\nThe trial was primarily about the safety of the procedure, and all eight patients came through without significant side effects, he said.\nThe study shed new light on a question of prime interest to cardiologists: whether the injected stem cells actually transformed themselves into heart muscle, or improved heart function in some other way.\nIt worked in patients such as Eaton, whose heart attack was 11 years ago, Hare said.\nBy implication, it almost certainly improves the patient's health, although that was not directly measured in the small, early study.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "This story does not interview any independent sources, nor does it reveal that some of the study authors received funding from BioCardia, the company that manufactures a device used to inject the stem cells into the participants\u2019 hearts. In addition, the story should have noted that the study was funded in part by BioCardia.\n", "answer": 0}, {"article": "Cortisol is known as the \u201cstress hormone\u201d because it is released in response to acute stress to help the body react and cope.\nBut it did reveal it was important to further study hormones and the body\u2019s endocrine system, and how they relate to mental illnesses like anxiety and depression, he said.\nThe greater number of traumatic events a child had experienced, such as divorce, injury, moving house, severe illness or the death of a family member, the higher the hair cortisol concentrations were, the researchers found.\n\u201cHowever, hair samples are not only easier to obtain, but provide us with a picture of total cortisol throughout the system across many months rather than just at a point in time,\u201d Simmons said.\n\u201cWhat\u2019s less commonly understood is that beyond poor mental health, it can also be associated with the development of other illnesses such as diabetes, obesity and cholesterol issues, because cortisol is also central to glucose availability, blood pressure and immune function, so identifying these children is important.\u201d\n\nWhile blood or saliva tests could be used to detect cortisol levels, these methods were sometimes problematic, especially in children, Simmons said.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "There are no conflicts of interest as determined from the authors\u2019 disclosures in the published study.\nBut the story quotes only the first author of the study in the article, and would have done well to get opinions of the work from at least one independent source. It\u2019s pretty unfortunate that\u00a0the story did not get an outside perspective, given the nature of the article and its claims.", "answer": 0}, {"article": "Yet stroke patients admitted on the weekends were no more likely to die than stroke patients admitted during the week: 1,420 patients admitted on the weekend died versus 3,993 patients admitted on a weekday, which worked out to roughly the same rate of death.\nThe current study, she added, shows that \u201chigh quality (stroke) care is available in hospitals on the weekends and weekdays.\u201d In fact, care might even be more aggressive on weekends.\nOverall, Kazley added, this study offers \u201cgood news that indicates that the quality of care is similar regardless of when patients present at the hospital for treatment.\n\u201cEven in a country with universal health insurance coverage (such as Canada), disparities in resources, expertise, or the number of healthcare providers working during weekends\u201d may affect the stroke mortality rate, the researchers concluded.\nStroke requires emergency treatment and for those suffering a stroke on a Saturday or Sunday, \u201cwaiting until Monday for aggressive treatment is not an option,\u201d Dr. Abby S. Kazley and colleagues from the Medical University of South Carolina in Charleston emphasize in a report released today.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "As noted above, the story quotes an independent expert who does not appear to have a conflict of interest regarding this issue.", "answer": 1}, {"article": "The investigators found that the less salt people ate, the more likely they were to die of heart disease \u2014 50 people in the lowest third of salt consumption (2.5 grams of sodium per day) died during the study as compared with 24 in the medium group (3.9 grams of sodium per day) and 10 in the highest salt consumption group (6.0 grams of sodium per day).\nBut, Dr. Alderman said, the new study is not the only one to find adverse effects of low-sodium diets.\nLowering salt consumption, Dr. Alderman said, has consequences beyond blood pressure.\n\u201cThey do not tell you what will happen if you change peoples\u2019 sodium intake.\u201d\n\nWhat is needed, Dr. Alderman said, is a large study in which people are randomly assigned to follow a low-sodium diet or not and followed for years to see if eating less salt improves health and reduces the death rate from cardiovascular disease.\n\u201cWe shouldn\u2019t be guiding any kind of public health decisions on it.\u201d\n\nDr. Michael Alderman, a blood pressure researcher at Albert Einstein College of Medicine and editor of the American Journal of Hypertension, said medical literature on salt and health effects was inconsistent.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story did a better job than USA Today finding experts who could give readers a broad context for the findings. We also appreciated how it noted that one of the experts had worked for the Salt Institute, which is the leading advocacy organization for more salt consumption.\n[Addendum on May 6: It\u2019s very difficult to find an \u201cindependent\u201d expert to comment on the evidence base on salt. Dr. Alderman, who is quoted in the Times story and frequently weighs in on this controversy, has an asterisk next to his name (appropriately so) because of his previous ties to the salt industry. But it\u2019s worth noting that the independent experts in this field, such as Dr. Appel and Dr. Sacks (who are also quoted in the Times story), are closely affiliated with NHLBI which funds much of the research on sodium. And as Gary Taubes posited many years ago in Science magazine, the NHLBI may not be a dispassionate arbiter of the evidence. (The full text of his story can be accessed at the National Association of Science Writers website: http://www.nasw.org/1999-science-society-awards.) ]", "answer": 1}, {"article": "Harvard T.H.\nOther Harvard Chan School researchers involved in the study included Heather Eliassen, associate professor in the Department of Epidemiology, and Xiaomei Liao, research scientist in the Departments of Epidemiology and Biostatistics.\nThe study was supported by National Institutes of Health grants R01 CA050385 and UM1 CA176726 and a grant from The Breast Cancer Research Foundation.\n\"From many other studies we know that breast tissue is particularly influenced by carcinogens and anticarcinogens during childhood and adolescence,\" said Walter Willett, Fredrick John Stare Professor of Epidemiology and Nutrition at Harvard Chan School and senior author of the study.\nThe study will be published online February 1, 2016 in Pediatrics.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The National Institutes of Health and The Breast Cancer Research Foundation are named as funders. An existing financial arrangement between a lead researcher and the Japan Pharmaceutical Manufacturers Association is also disclosed in the release. It\u2019s not at all clear how this trade group was involved with the study or how its interests dovetail with a fiber-rich diet.", "answer": 1}, {"article": "Current methods for determining if a prostate has become cancerous include a physical examination of the prostate (known as a digital rectal examination or DRE), MRI scans, a biopsy or tests to determine levels of the chemical prostate-specific antigen (PSA) in the blood.\nWe can now see with much greater accuracy what tissue is cancerous, where it is and what level of treatment it needs.\nThe Dundee University-based team say they have used an ultrasound process called shear wave elastography (SWE) to detect prostate tumours.\nHowever, to make it applicable to prostate cancer a special probe had to be developed by the team.\nOne in eight men will develop the condition at some point in their lives with more than 47,000 new cases being diagnosed every year.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "All of the sources in the story were the same sources in the news release.\nThere is no mention of potential conflicts of interest among the researchers, even though this is a new technology which, if successful, could profit the researchers/inventors.", "answer": 0}, {"article": "Cannabidiol, or CBD, is a compound in the cannabis plant that does not contain psychoactive properties that induce a high.\nGW Pharmaceuticals funded the clinical trial.\nThe new study confirms results from a December 2015 open-label expanded access program led by Dr. Devinsky that reported reductions in seizure frequency.\nFor the study, 120 children and adolescents with Dravet Syndrome between the ages of 2 and 18 years were randomized across 23 sites in the United States and Europe to receive either CBD 20 mg/kg or placebo added to their existing treatment over a 14-week period.\nThe study included a liquid pharmaceutical formulation of CBD, called Epidiolex, which is manufactured by GW Pharmaceuticals and has not been approved by the U.S. Food and Drug Administration.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release mentions that the trial was funded by GW Pharmaceuticals, the manufacturer of Epidiolex.", "answer": 1}, {"article": "Since IVM results in lower fertilization rates, protocols that use IVM are more likely to also use intracytoplasmic sperm injection (ICSI), in which one sperm is injected into one egg.\nFor starters, since there is less time involved with IVM, women who are undergoing chemotherapy, radiation or plan to have surgery may be good candidates.\nThey also note that the technology hasn\u2019t been widely used and that there are no studies looking at the outcomes of birth defects or developmental delays.\nIVM can also help women who are adverse to injections or who have failed IVF, Luk said.\nIVM has the potential to improve the chances for women to have babies without a long course of hormones.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The article does quote two sources who were apparently interviewed, although both are principals in reproductive medicine clinics selling their services.", "answer": 1}, {"article": "MRI uses a powerful magnetic field and pulses of radiowave energy to create images.\nIndeed, CT appears to be better for assessment of coronary artery disease, matched against not only MRI but other methods, such as echocardiography, he said.\nThat difference helps explain why there are so few studies doing head-to-head comparison of CT versus MRI, he said.\nIndeed, CT and MRI are not contenders in clinical practice but are used for different reasons to make different assessments, Schoepf said.\nCT is the preferred noninvasive technology for assessing the condition of heart arteries, whether there is narrowing that might end with the total blockage that causes a heart attack, Schoepf said.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story does cite two independent sources who appeared unrelated to the study.\nThe story did not identify any potential conflicts of interest. While the study publication identifies no primary funding sources, the senior author, Marc Dewey,\u00a0reports in his conflict of interest statement financial relationships with\u00a0Toshiba Medical Devices, Bayer-Scherling, and Guerbet, companies that manufacture imaging devices or contrast media used with them. These relationships were disclosed by the medical journal when they published the study \u2013 yet the story makes no menton of them.", "answer": 0}, {"article": "Both groups went to their V.A.\nBased on the study results, it could be that patients need to renew their regimen with the cream every year.\nThe study did show a significant decrease in the risk of needing Mohs surgery to treat a BCC in the first year.\nThe finding that less than one month's use of fluorouacil 5% (5-FU) appeared to prevent cancer for up to a year is encouraging, said lead author Dr. Martin A. Weinstock, a professor of dermatology in the Warren Alpert Medical School of Brown University and chief of dermatology at the Providence Veterans Affairs Medical Center.\nBut after six months and again at the end of the four-year trial, 87 percent of participants in the 5-FU group said they'd be willing to repeat the treatment if it proved effective in reducing skin cancer.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release points out that the study was funded by the Veterans Administration but omits the fact that several members of the research team received support from pharmaceutical firms. However, there\u2019s no indication that those connections played any role in the conclusions from the trial.", "answer": 0}, {"article": "One therapy at M.D.\nNow, because drugs are mostly tested on patients whose cancer has resisted previous treatment, it's usually used on tumors advanced to often fatal stages.\nAs a result, the researchers are now giving one-two punches of drugs that energize the immune system and direct it to go after cancer cells it had hardly noticed.\nThe treatment \u2014 shots that grab the immune system and jolt it to fight against rebel tumor cells \u2014 has been a dream for more than a century.\nThe new knowledge, much of it thanks to the genomics revolution, is helping cancer scientists remedy that.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes two MD Anderson researchers as well as a scientist at the NCI, who provides much needed balance at the end of the story.", "answer": 1}, {"article": ".\n\"Much of the variation in the published study findings can be explained by the daily dose of zinc administered in the zinc lozenges,\" said Hemila, who funded the research himself.\nAllowing the lozenge to dissolve instead of swallowing it seemed to provide a therapeutic effect.\n\"When focusing on those studies which have used large daily doses of zinc, there is strong evidence that zinc lozenges shorten the duration of colds.\"\nWhile surprised to note how strong the correlation was between daily doses of zinc and its effect on colds' duration, he said he and his colleagues still don't know why it seems to work.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes the author of the original journal article and one expert. Neither of these appear to have conflicts of interest.", "answer": 1}, {"article": "Type 2 diabetes is the most common form of the disease and is linked to obesity.\nZinman, in an interview, predicted the new study would prompt medical societies to recommend that Jardiance be used by type 2 diabetics who have a history of heart disease or who are at risk of cardiovascular events.\nIn calculating the combined number of cardiac deaths, non-fatal heart attacks and non-fatal strokes, 14 percent fewer events were seen in patients taking Jardiance in combination with standard treatments, compared with patients who took standard treatments alone, meeting the study\u2019s main goal.\nHe has not prescribed Jardiance and similar drugs as frequently as treatments like Januvia, but expects that may change based on the new data.\nThe benefits were especially impressive because they added to protection that patients received from taking cholesterol fighters and other life-saving heart drugs, Zinman said.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The initial version of this story includes only comments from Dr. Bernard Zinman, the lead investigator. The updated version of the story includes additional perspectives on the research, but neither version of the story makes it clear the the study was funded by\u00a0Boehringer Ingelheim and Eli Lilly, or that Dr Zinman and other co-authors disclosed financial relationships with Boehringer Ingelheim related to the study and outside of the study.", "answer": 0}]